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The frontline antimalarial Artemisinin is decreasing in efficacy across the Greater
Mekong Subregion. The study of  parasites from this region has led several au-
thors to propose that Plasmodium falciparum may be able to enter state of  dormancy—
programmed cell cycle arrest—as a means of  drug resistance. An independent line
of  reasearch recently described a similar dormancy-like state in vitro when P. falciparum
parasites are starved of  the essential amino acid isoleucine, raising the possibility that
a shared genetic pathway may underlie survival of  both starvation and drug treat-
ment. Here, we revisit and expand upon the dormancy-like response of P. falciparum
to isoleucine starvation. We have found that the parasite does not exit the cell cycle
upon starvation, but instead enters a state of  slow growth. This change in growth rate
occurs only if  isoleucine is removed prior to the onset of  S-phase. After DNA replica-
tion has begun, the parasite traverses the cell cycle at its normal pace, and only enters
slow growth in the next generation; a response reminiscent of  the nutrient-dependent
G1 cell cycle checkpoints described in other organisms. We have also implicated the
P. falciparum ortholog of  the RNA Polymerase III repressor Maf1 in maintaining via-
bility of  parasites undergoing starvation-induced slow growth. Parasites defective in
Maf1 expression fail to shut-down tRNA expression and display decreased growth
and survival under a number of  growth-limiting treatments. Lastly, we have assayed
the ability of  an Artemisinin-resistant field isolate to survive long term isoleucine star-
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vation and found that resistant parasites display increased recovery from isoleucine
deprivation. Combined, these results suggest that while the parasite may not exit the
cell cycle as in the dormancy responses of  other organisms, P. falciparum possesses
growth regulatory pathways that can affect the parasite’s ability to survive growth-











Hofstadter’s Law: It always takes longer than you expect, even when you take
into account Hofstadter’s Law.
—Douglas Hofstadter
Gödel, Escher, Bach: An Eternal Golden Braid
1979
With one more victory like this, we shall be utterly ruined.
—Pyrrhus of  Epirus
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Recrudescence, Relapse, and Dormancy
It has long been known that clinical malaria can recur in patients months after the in-
dividual has left an endemic region. Shute was the first to classify these “long-latency-
infections” into two groups: Recrudescence and Relapse (Shute, 1946). Recrudescence is
generally attributed to insufficient chemotherapy or the emergence of  drug-resistant
parasites. Symptomatic malaria disappears after the initial treatment due to the sup-
pression of  parasite numbers, but returns as the few surviving parasites re-establish
themselves.
Relapse was used to describe the long latency periods regularly observed between
episodes in patients suffering from benign tertian malaria—what we know today to be
Plasmodium vivax infection. The observation that relapse never occurred when infec-
tion was intiated from blood transfusion (Shute, 1946), and that Plasmodium sporo-
zoites could survive for long periods in the mosquito salivary glands led to the hy-
pothesis that Plasmodium vivax was able to enter a state of  dormancy after being inoc-
ulated by the mosquito into the human host. The later discovery of  what appeared
to be latent parasite stages in the livers of  chimpanzees experimentally infected with
Plasmodium vivax (Krotoski et al., 1982) solidified the formulation the hypnozoite hypoth-
esis (Krotoski, 1985): Plasmodium vivax (as well as the human P. ovale and the simian
P. cynomolgi, P. fieldi, and P. simiovale) is capable of  entering a programmed state of  de-
velopmental arrest within hepatocytes prior to blood stage infection. Relapse occurs
when this dormant hypnozoite stage reactivates months or years after initial infection
and commences the intraerythrocytic cycle.
No developmentally arrested parasites have ever been observed in liver cells
after infection with Plasmodium falciparum. And yet, while less common than with Plas-
modium vivax, there is an extensive literature on the recurrance of P. falciparum malaria
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after long periods of  latency in cases where de novo mosquito transmission can be
decisively ruled out (Ashley and White, 2014). In the most extreme case, a patient
contracted P. falciparum after a blood transfusion from a donor that had not traveled
to an endemic region for over thirteen years (Besson et al., 1976). Often, recurrent
patency follows a traumatic event, such as surgery, a severe wound, famine, or war
(Shanks, 2015), suggesting reemergence of  the parasite is triggered by changes in
host physiology, much they way P.vivax relapse is believed to be triggered for reacti-
vation (Shanks and White, 2013). Formally, these events are considered to be cases
of Recrudescence. It is presumed the afflicted individuals were continuously infected but
simply asymptomatic during the prolonged latency periods. The parasite is thought
to be maintained at low levels through the actions of  the host’s immune system, and
only increases to a density capable of  causing clinical disease when the immune sys-
tem wanes for any number of  reasons. However, recent observations may suggest an
alternate explanation.
Studies of  the decreased efficacy of  artemisinin-based anti-antimalarials in the
field has found persistent ring stage parasites in the blood hours after parasites would
normally be expected to be cleared (Dondorp et al., 2009). Supporting in vitro studies
have also observed peculiar developmentally arrested parasites after artemisinin treat-
ment, leading several authors to suggest P. falciparum may enter a state of  dormancy as
a mechanism of  drug resistance (Teuscher et al., 2010)(Witkowski et al., 2010)(Codd
et al., 2011)(Cheng et al., 2012). In an intriguing parallel line of  research, a study
found that starvation of  the essential amino acid isoleucine can trigger a dormancy-
like state in blood stage P. falciparum (Babbitt et al., 2012). If  these studies hold true,
then the distinction between Recrudescence and Relapse in cases of falciparum malaria may
need to be re-evaluated.
The work reported in this thesis is aimed at investigating and evaluating the na-
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ture of  these dormancy-like states of P. falciparum in in vitro culture. Chapter 2 is a study
of  the response of  the parasite to isoleucine starvation as it relates to cell cycle pro-
gression and the observed dormancy-like survival mechanism of  artemisinin-resistant
field isolates. Chapter 3 is an analysis of  a mutant parasite line incapable of  surviving
prolonged amino acid starvation and a discussion of  the conserved eukaryote genetic
pathways that regulate growth arrest and recovery. Chapter 4 is a slight departure, and
details a study of  the genetic basis of  sexual differentiation in the parasite, and its
relation to cell cycle progression and growth.
As of  the end of  2015, ninety-five countries across the globe still experience on-
going malaria transmission, leading to more than two hundred million cases and over
four hundred thousand deaths each year (World Health Organization, 2015). De-
spite great successes in the last fifteen years in decreasing incidence (18% decrease)
and death (48% decrease)(World Health Organization, 2015), Plasmodium falciparum re-
mains a substantial public health burden. Further insights into the nature of  the par-
asite life cycle and transmission dynamics, including the possibility of  programmed
blood stage dormancy as a mechanism of  drug resistance and relapse, promise to




The dormancy-like response to isoleucine





It has been reported that the malaria parasite Plasmodium falciparum enters a dormancy-
like state upon starvation of  the essential amino acid isoleucine by first slowing its
cell cycle and then arresting prior to S-phase. We have reexamined this response
and found that the parasite does not exit the cell cycle prior to DNA replication,
but instead, continuously grows at a dramatically reduced pace. Moreover, slow
growth occurs only if  isoleucine is removed prior to the onset of  schizogeny. After S-
phase has commenced, the parasite is insensitive to isoleucine depletion and transits
through the cell cycle at the normal pace, reminiscent of  the nutrient-dependent G1
cell cycle checkpoints described in other organisms. Similar to isoleucine-starvation,
artemisinin derivatives have also been reported to induce growth retardation in ring-
stage parasites, and resistant parasites carrying variants of  the K13 gene have been re-
ported to survive drug-treatment due to an increased capacity to resume growth after
drug concentrations have declined. We show that one such artemisinin-resistant K13
mutant parasite line displays increased survival upon prolonged isoleucine-induced
growth retardation, suggesting a connection between the underlying molecular path-





Dormancy is a strategy used by many organisms to overcome unfavorable environ-
mental conditions. While the term is often used loosely, in its strictest sense in uni-
cellular organisms, dormancy typically refers to an exit from the mitotic cell cycle and
differentiation into a distinct cellular state (i.e.: G0), that exhibits low metabolic ac-
tivity. The Plasmodium life cycle includes several stages of  programed dormancy such
as the mature gametocyte, the salivary gland sporozoite, and the poorly understood
hepatic hypnozoites of  certain Plasmodium species. These are specialized differentiated
cells with low metabolic activity, capable of  waiting long periods before activating and
re-entering the cell cycle.
In recent years, the frontline antimalarial drug artemisinin has been exhibiting
decreased efficacy in clearing Plasmodium falciparum from the blood stream in regions
of  South East Asia. While there has yet to be widespread clinical failure, parasite iso-
lates that display delayed clearance, detectable in the blood as ring stages hours after
artemisinin therapy, are referred to as artemisinin resistant (Dondorp et al., 2009).
The fact that this resistance phenotype manifests as the persistence of  a defined
morphological stage (ring), and the fact that artemisinin is most effective when
parasites are actively metabolizing hemoglobin in the trophozoite stage and later
(Klonis et al., 2013), has led several authors to propose a dormancy model of
artemisinin resistance (Kyle DE, Webster HK, 1996)(Hoshen et al., 2000)(Teuscher
et al., 2010)(Witkowski et al., 2010)(Codd et al., 2011) (Cheng et al., 2012). In
this model, non-hemoglobin digesting ring stage parasites exit the cell cycle upon
artemisinin treatment and assume an arrested state of  low metabolic activity for a
prolonged period until drug concentrations have decayed (Figure 2.1A). It is not
clear how artemisinin would trigger such a response, as the drug itself  is unlikely to
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be a natural trigger for the dormancy pathway. Instead, it is more likely that there is
a pre-existing dormancy response in the intraerythrocytic cycle and resistant isolates
have acquired mutations that allow the co-option of  this pathway when under drug
pressure.
In many organisms, differentiation into a dormant state is triggered by unfavor-
able nutrient conditions. In human cells in culture, removal of  serum growth factors
causes G1 cells to exit the cell cycle and enter a state of  quiescence (Pardee, 1974).
Similarly, in haploid stages of  the yeast Saccharomyces cerevisiae, starvation of  nitrogen
or carbohydrates during the G1 phase causes an arrest of  the mitotic cycle and entry
into a dormant state that can be maintained for a prolonged period with little loss of
viability (Lillie and Pringle, 1980). In a recent landmark study, Babbitt et al. reported
that Plasmodium falciparum enters an analogous dormancy-like state when starved of
the essential amino acid isoleucine (Babbitt et al., 2012).
During the intraerythrocytic life cycle, Plasmodium falciparum acquires most of
its amino acid supply through the digestion of  hemoglobin. However, as human
hemoglobin does not contain isoleucine and the parasite cannot synthesize it de novo,
it must obtain isoleucine from the extracellular environment (human serum or culture
medium in vitro). In human blood, isoleucine concentrations can drop well below the
levels needed to support P. falciparum growth in culture (Baertl et al., 1974)(Liu et al.,
2006), which would be lethal for the parasite without an adaptive mechanism. When
starved of  isoleucine, Babbit et al. reported that the parasite dramatically slows its cell
cycle, eventually arresting prior to DNA synthesis (Figure 2.1B). The parasite can
remain in this state of  low metabolic activity for upwards of  several days, and then
resume growth with little loss of  viability upon isoleucine resupplementation. In





The similarities between the observed response of  resistant parasites to
artemisinin derivatives in vivo and isoleucine-starved parasites in vitro suggested
further investigation for potential overlap of  the underlying molecular pathways.
Here, we revisit and expand upon the isoleucine-induced dormancy-like state. Our
results suggest that the pathways necessary for growth modulation and recovery
upon artemisinin treatment may be the same or overlap with those required for
maintaining viability during the dormancy-like state induced by isoleucine starvation.
Results
Plasmodium falciparum completes the cell cycle in the dormancy-like state in
the absence of extracellular isoleucine
Babbitt et al. reported that when young rings are deprived of  extracellular isoleucine
the parasites enter a phsysiological state reminiscent of  hibernation or aestivation in
higher animals: a reversible state of  low-metabolic activity and high resource con-
servation (Babbitt et al., 2012). When resupplemented with isoleucine, parasites im-
mediately resumed normal growth, displaying only modest losses in viability after
72h of  starvation. Over the course of  isoleucine starvation, the parasite’s progression
through the cell cycle was drastically retarded, advancing at 40% of  the pace of  control
cultures until seemingly arresting as hemozoin-containing, pre-S-phase trophozoites.
We repeated the Babbit et al methodology to verify that the phenotype held for the
NF54 clone of P. falciparum used in our laboratory.
As observed by Babbit et al., young rings (~6 hpi) washed thoroughly with PBS
and transferred to culture medium lacking isoleucine remained at the starting para-
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sitemia after 72 h, whereas control parasites (standard RPMI 1640 with 382 µM Ile)
completed a cell cycle and re-invaded red blood cells over the same time period (Fig-
ure 2.2). When the starved parasites were resupplemented with complete medium for
72h, they displayed growth similar to the control cultures that had never been starved
(Figure 2.2). Thus, the isoleucine response described by Babbit et al. is robust and
reproducible in this parasite clone.
Over the course of  our experiments, we noticed the appearance of  parasites with
greater than 1C DNA content in cultures deprived of  isoleucine for over 48h, sug-
gesting that, despite growth retardation, some parasites were able to commence DNA
synthesis in the absence of  isoleucine. This observation was not noted by Babbit et
al., however, most of  their study focused on earlier time points. To investigate this
in more detail, we initiated isoleucine-starved and isoleucine-normal cultures from
late-stage, percoll-isolated schizonts and tracked their development over the ensuing
six days.
Control parasites developed as expected, with schizonts appearing in Giemsa-
stained smears roughly every 45 h, followed by an increase in parasitemia with each
generation (Figure 2.3, Figure 2.5A). DNA content analysis by flow cytometry was
used to track the proportion of  1C DNA content parasites at each time point, and
displayed a 45 h periodicity for 1C peaks (Figure 2.4).
Isoleucine-starved parasites also progressed through the cell cycle, albeit at a
much reduced pace (Figure 2.3). Using a correlative transcriptome analysis, Babbitt
et al. calculated that isoleucine-deprived young rings traversed the cell cycle at a pace
40% of  that of  controls over 48 h of  analysis (Babbitt et al., 2012). However, they
concluded that the parasites did not progress further into S-phase of  the cell cycle. In






the first rings of  the second generation were observed at 100 h of  incubation. DNA
content tracking of  1C parasites also revealed an extended periodicity of  roughly 90h,
corresponding to at least a 50% reduction in the pace of  the cell cycle (Figure 2.4).
It appears the isoleucine-starved parasites do not arrest pre-S-phase to asssume a
dormant state, but instead continuously progress through the cell cycle at a retarded
pace.
It should be noted that the isoleucine-withdrawal-induced growth retardation is
not without its costs. While control parasites increased in parasitemia with each gen-
eration, the isoleucine-starved parasites decreased in numbers at a modest, but steady
rate over the course of  a six-day incubation (Figure 2.5A). This suggests that, despite
completing the cell cycle and re-invading at roughly four-day intervals, the overall
viabilty of  the slow growing parasites decreased as starvation progressed. This is in
agreement with Babbitt et al.’s observation of  diminished recovery upon isoleucine
resupplemenation as a function of  increased starvation. The cause of  this loss of  via-
bility is not clear, however, the mean DNA-content of  parasites at schizont-enriched
time points was substantially lower for isoleucine-starved parasites compared to con-
trols (Figure 2.5B). This suggests that either isoleucine starvation produced schizonts
with a lower average merozoite count, decreasing the growth potential of  each cell,
or that a majority of  cells experienced catastrophic failure early in schizogeny and
produced no viable progeny.
The dormancy-like slow growth response is cell cycle stage-dependent
Mammalian cells respond to serum starvation by exiting the cell cycle and entering a
quiescent state (Pardee, 1974). However, this quiescence-response program is only
induced if  serum is removed prior to a specific point in the cell cycle known as the
15
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Restriction Point. Once this Restriciton Point is crossed, the cells become refractory to
the serum starvation, and continue on with the mitotic cell cycle to produce daugh-
ter cells. The daughter cells once again become sensitive to the serum starvation until
they too cross Restriction Point and become refractory. A similar phenomenon occurs
in the haploid stages of  the yeast Saccharomyces cerevisiae with a time threshold referred
to as Start. Yeast cells starved of  nitrogen or glucose, or treated with mating factor
prior to Start will differentiate into stress tolerant stationary phase cells or commit
to the mating pathway (Hartwell et al., 1974)(Hartwell, 1974). Once Start is crossed,
yeast cells commit to cell division and are refractory to the starvation or mating fac-
tor stimulus. We investigated whether the dormancy-like slow growth response to
isoleucine starvation in P. falciparum exhibited a similar cell cycle stage-dependent re-
fractoriness to nutrient removal.
A culture of  highly synchronous young rings was initiated in normal culture
medium. At three hour intervals, an aliquot of  the culture was removed, washed
repeatedly to remove any traces of  isoleucine, and resuspended in medium lacking
isoleucine. After 30 h or 60 h of  incubation (for time points >24 h or <24 h respec-
tively), the parasitemia of  the cultures was quantified by flow cytometry to determine
the relative growth of  each sample over the analysis period.
As expected from earlier experiments, young rings remained at roughly the start-
ing parasitemia over the course of  the incubation. However, as the post-invasion age
of  the culture increased, a notable increase in the final parasitemia became evident
(Figure 2.6). A logistic regression performed on the data confirmed that the likeli-
hood of  completing the cell cycle increased as the age of  the culture at the time of
isoleucine removal increased. Based on the logistic model fit to the data, at approxi-
mately 30 h post-invasion, 50% of  parasites transferred from normal culture medium




by Babbitt et al, while the remaining 50% continue through the cell cycle to comple-
tion at the normal pace and enter the slow-growth response in the subsequent cycle.
Beyond 30 h, an increasing number of  parasites complete the cell cycle uninhibited
by the absence of  isoleucine.
The Restriction Point in mammalian cells and Start in yeast represent a “point of  no
return” in commitment to the cell cycle, typically referred to as a cell cycle checkpoint.
These checkpoints arise due the irreversible positive-feedback loops regulated by the
underlying molecular interactions of  cyclins, cyclin-depdendent kinases (CDKs), and
their downstream targets. Checkpoints that regulate the exit from the mitotic cycle
and into a state of  quiescence or differentiation typically occur prior to commence-
ment of  S-Phase, and for this reason, are generally referred to as a G1 Checkpoints.
The time-dependent binary response of P. falciparum to isoleucine withdrawal fits well
within the classical definition of  a cell cycle checkpoint. However, without evidence
for the involvement of  cyclins or cyclin-dependent kinases, we consider this assign-
ment to be tentative. The data suggest that some molecular changes occur at around
the 30 h into the cell cycle to render the parasite refractory to isoleucine withdrawal.
The isoleucine refractory point coincides with the onset of DNA synthesis
Inferring cellular events in the Plasmodium cell cycle based on time estimates alone can
be misleading, as the methods used for synchronization are imperfect, and the in vitro
length of  the intraerythrocytic cycle has been reported to range anywhere from 38
h to 50 h for different parasite isolates and clones (Babbitt et al., 2012)(Reilly et al.,
2007). To get a more definitive understanding of  what this underlying event may be,





The transition of  the parasite from the ring stage to the trophozoite stage is
marked by a dramatic change in the permeability of  the host erythrocyte to a range
of  solutes. This New Permeability Pathway (NPP) is due to the activation of  a parasite-
derived or modified pump in the host plasma membrane (Desai, 2012). Isoleucine is
one of  the biologically relevant solutes affected by the NPP. While erythrocytes dis-
play a basal permeability to isoleucine via the host L-system, activation of  the NPP
increases isoleucine uptake by 5-fold (Martin and Kirk, 2007). In vitro, NPP activa-
tion renders parasites permeable to sorbitol, which leads to rapid lysis of  infected
erythrocytes with an active NPP (trophozoites and schizonts), but leaves imperme-
able cells (rings stages) unharmed. This property provided the basis for the preferred
method for ring-stage synchronization (Lambros and Vanderberg, 1979). The ring-
to-trophozoite transition and by extension activation of  the NPP, should occur well
before the 30 h mark of  a 45 h parasite cell cycle. However, given the role of  the
NPP in isoleucine uptake and the feasibilty with which NPP activation can be as-
sayed, we re-determined the timing of  the isoleucine refractory point in relation to
NPP activation.
As before, synchronous young rings in normal medium were transferred to
medium lacking isoleucine at three-hour intervals across the 45 h life cycle. At each
time point, duplicate aliquots of  culture were treated with 5% w/v sorbitol and re-
suspended in normal culture medium for a 72h recovery period. The relative growth
of  the two treatments is plotted in Figure 2.7A. As with isoleucine withdrawal, a lo-
gistic regression fit to the sorbitol treated cultures shows a marked time-dependent
response. Sorbitol treated samples dispaly decreased growth with increasing parasite
age post-invasion, as would be expected from parasites becoming susceptible to sor-
bitol lysis as they reach the point of  NPP activation. Notably, the logistic model fit
to the data maps the 50% relative survival point for sorbitol treament (23.3+/-0.4 h)




Another molecular milestone in the Plasmodium cell cycle is the establishment of
the Plasmodium Translocon of  Exported Proteins (PTEX) complex for export of  spe-
cific parasite proteins across the parasitophorous vacuolar membrane into the host
erythrocyte. Protein export is generally thought to occur in the early trophozoite.
Beck et al. (Beck et al., 2014), produced a transgenic parasite line in which an essential
component of  the PTEX complex, Hsp101, was modified such that its activity could
be regulated by the chemical ligand trimethoprim (TMP). Removal of  TMP from the
culture medium leads to inhibition of  Hsp101 function, blocking protein export by
the PTEX complex. When TMP was removed from the culture at the ring stage,
parasites arrested growth as morphological rings, but could resume growth without
a loss in viability if  the culture was resupplemented with TMP within 48 h. However,
if  TMP was removed from the culture during the mid-trophozoite phase, the para-
sites completed the cell cycle unperturbed and reinvaded new cells whereupon they
arrested at the late ring stage (Beck et al., 2014). This suggests that establishment of
the PTEX complex is another checkpoint-like event in the Plasmodium cell cycle. Beck
et al. generously provided us with the 13F10 Hsp101-DD 3D7 clone used in their
study so we could test whether the PTEX-dependent checkpoint-like event overlaps
with isoleucine refractory point.
Again, synchronous young rings were sampled at three-hour intervals across
the cell cycle and transferred either to medium lacking isoleucine (but supplemented
with TMP), or normal medium lacking TMP. The relative growth of  each sample is
plotted in Figure 2.7B. Logistic regression models fit to both treatments show a time-
dependent binary response. However, once again, the 50% growth point for PTEX-
dependent growth-arrest (17.8+/-0.4 h) is well ahead of  the isoleucine-dependent
growth-retardation point (here 27.4+/-0.4 h). The 3D7 Hsp101-DD clone used for
this assay displays a shorter cell cycle time than our normal NF54 clone, which likely
contributes to the slightly earlier timing the isoleucine response point. While it is dif-
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ficult to project the PTEX-arrest point onto the sorbitol-NPP point calculated above
in our NF54 clone, Beck et al. demonstrated that PTEX-arrested parasites were resis-
tant to sorbitol treatment, placing activation of  the NPP after PTEX establishment.
The 30-hour time point predicting the response of  parasites to isoleucine depri-
vation lies after two of  the molecular events traditionally associated with trophozoite
stage of  the cell cycle. We next tested where it mapped relative to the transition
into S-phase and schizogeny. Synchronous young rings were once again transferred
from normal medium into isoleucine-depleted medium at three-hour intervals. At
each time point, aliquots were fixed, permeabilized, and stained with SYBR GREEN
I for DNA content analysis by flow cytometry (Figure 2.8). A logistic regression
model fit to the proportion of  parasites with >1C DNA content overlaps with the
proportion of  parasites continuing normal growth, with 50% of  the parasites transi-
tioning from 1C DNA content to >1C content (29.9+/-0.5h) at a point indistinguish-
able from the point at which 50% of  the parasites become refractory to isoleucine
starvation (29.4+/-0.4h). In fact, when a regression model was fit with both age
post-invasion and proportion of  >1C parasites as factors, the DNA content alone
predicts the response of  the parasites to isoleucine. From the same data, we also
tested where the transition from <2C to >2C DNA content occurred relative to
the isoleucine-dependent point. While temporally close, the transition to from <2C
to >2C (31.7+/-0.5h) occurs after cells have become refractory to the removal of
isoleucine (Figure 2.9).
When deprived of  extracellular isoleucine, Plasmodium falciparum enters a re-
versible slow growth program of  low metabolic activity in which it progresses
through the cell cycle at approximately half  its normal pace (Figure 2.10). The
parasite can complete the cell cycle and invade erythrocytes anew in the complete





replication has commenced, the parasite does not enter the slow program and
instead continues its mitotic cycle at the normal pace. This behavior is reminiscent
of  classic G1 checkpoint events such as the Restriction Point in mammalian cells and the
Start Checkpoint in S. cerevisiae. It remains to be shown whether this stage-dependent
response can be directly attributed to events involving cyclins and CDKs of  the
cell cycle, as it is in other system. The mechanism by which the parasite detects
isoleucine withdrawal to modulate its growth rate in G1 also remains unknown,
however, recent evidence the artemisinin-resistance literature offers some potential
clues.
PfPI3K inhibition induces growth retardation similar to isoleucine starvation
Our understanding of  the molecular basis for delayed-clearance of  certain field iso-
lates upon artemisinin treatment has advanced greatly in recent years. The ring-stage
of  any Plasmodium isolates (artemisinin “resistant” or sensitive) is much less sensitive
to artemisinin than later stages of  the parasite (Klonis et al., 2013). This is because
the heme released from hemoglobin digestion in trophozoite and schizont stages
activates the drug’s epoxide ring, leading to oxidative damage (Klonis et al., 2011).
In rings, a brief  six-hour treatment with a sub-lethal dose of  artemisinin in-
duces a slowing of  the cell cycle reminiscent of  that induced by isoleucine depriva-
tion (Klonis et al., 2011). When high, clinically-relevant doses of  dihydroartemisinin
(DHA) are used in vitro, only artemisinin-resistant field isolates are able to recover
after growth-retardation (Dogovski et al., 2015). This DHA-induced slow growth
likely accounts for the delayed ring clearance phenotype observed in vivo. Thus, resis-
tance to artemisinin is not due to an exit from the mitotic cycle into a dormant state,




of  parasites to recover and resume growth after a transient slowing of  the cell cycle,
much like we have observed during isoleucine starvation. The mechanistic basis of
this ability to recover from artemisinin-induced growth retardation is still being elu-
cidated. However, recent observations have identified additional similarities to the
isoleucine slow growth response.
Genomic analyses of  delayed clearance isolates identified mutations in the kelch-
propeller domain of  the previously uncharacterized K13 gene (PF3D7_1343700)
(Ariey et al., 2014). When these mutant K13 alleles of  artemisinin-resistant field iso-
lates were reverted back to the 3D7 “wild type” allele, the parasites were rendered sus-
ceptible to DHA treatment (Straimer et al., 2015). Similarly, the introduction of  the
different mutant K13 alleles into artemisinin sensitive lab strains rendered parasites
resistant to clincially-relevant DHA concentrations (Ghorbal et al., 2014)(Straimer et
al., 2015). These results have led to the conclusion that mutations in K13 are likely
responsible for the observed in vivo delayed clearance phenotype.
A single study has put forth evidence for the molecular basis underlying
K13-mediated artemisinin resistance. Mbengue et al. reported that, in the absence
of  hemoglobin digestion, artemisinin derivatives specifically inhibit the Plasmodium
Class III Phosphositide 3-kinase (PI3K) (PF3D7_0515300) (Mbengue et al., 2015).
The K13 protein product normally targets PI3K for destruction by the ubiquitin-
proteasome pathway, however, K13-mutations decrease the interaction needed for
ubiquitination, leading to higher protein levels of Pf PI3K. As a result, parasite
lines with higher PI3K levels exhibit increased resistance to artemisinin derivatives
(Mbengue et al., 2015).
Class III PI3Ks are known for catalyzing the assembly protein complexes at
intracellular membrane surfaces. They are essential components of  the endocytosis
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and autophagy machinery, two processes used for the acquisition and reclamation of
amino acids (Backer, 2008). In mammalian cells, several studies have also implicated
the Class III PI3K Vps34 in sensing and signaling of  intracellular amino acid levels
as part of  the mTOR pathway (Gulati et al., 2008)(Munson et al., 2015)(Yoon et al.,
2011)(Nobukuni et al., 2005)(Byfield et al., 2005)(Yan et al., 2009); a pathway known
to regulate progression through the cell cycle in response to nutrient levels.
The Plasmodium falciparum PI3K has been previously implicated in the endocyto-
sis and trafficking of  hemoglobin from the host cell into the parasite digestive vacuole.
Chemical inhibition of Pf PI3K causes accumulation of  hemoglobin-containing ves-
sicles in the parasite cytoplasm (Vaid et al., 2010). Artemisinin has also been reported
to block hemoglobin import (Hoppe et al., 2004) (Klonis et al., 2011). Vaid et al. con-
cluded that PI3K inhibitors induces growth-retardation upon blocking hemoglobin
uptake, although they did not directly measure advancement through the cell cycle
(Vaid et al., 2010). Nonetheless, this potentially explains the mechanism of  growth
retardation observed upon artemisinin treatment.
We revisited this effect by treating young ring NF54 parasites (artemisinin-
sensitive) to a high, six-hour dose of  the PI3K inhibitor LY294002 using a method
adapted from the standard Ring-stage Survival Assay (RSA) used to evaluate
artemisinin resistance (Witkowski et al., 2013). By monitoring the DNA content of
the culture at 32 h and 72 h after treatment, it was evident that PI3K-inhibited cells
were growth-retarded much like parasites deprived of  extracellular isoleucine (Figure
2.11). PI3K-inhibited or isoleucine-starved parasites displayed a predominantly
1C DNA content at 32 h when controls had progressed into schizogeny. By 72 h
post-treatment, controls had completed the cell cycle and were predominantly at the





The artemisinin-resistant K13 allele confers an increased growth rate
Direct Pf PI3K inhibition retards the Plasmodium cell cycle. It is not clear whether this
is due to inhibition of  amino acid acquisition or another mechanism. Artemisinin-
resistant K13 mutants have been reported to have increased intracellular Pf PI3K lev-
els and increased Pf PI3K activity (Mbengue et al., 2015). Given that Pf PI3K inhibi-
tion can slow growth, we investigated whether elevated Pf PI3K activity can enhance
growth. Straimer et al. produced lines of  several artemisinin-resistant field clones that
are syngenic to originals save for reversion of  the single amino acid mutation in the
K13 gene back to the artemisinin-sensitive allele (Straimer et al., 2015). We evalu-
ated the growth of  one of  these clones and its artemisinin-resistant counterpart (K13
allele R593T, isolated from Battambang, Cambodia) in normal culture medium over
18 days of  growth. The artemisinin-resistant isolate displayed a significant increase
in growth rate relative to its revertant counterpart (Figure 2.12A).
Plasmodium falciparum growth in vitro is unaffected by variation in the concentra-
tion of  isoleucine above 20 µM (standard RPMI 1640 concentraion is 382 µM) (Liu et
al., 2006). Below 20 µM, the parasite exhibits a concentration dependent decrease in
growth before entering the dormancy-like slow growth state (Liu et al., 2006) (Bab-
bitt et al., 2012). We found 8 µM isoleucine to be the lowest concentration capable of
supporting longterm, albeit slow growing, culture. We assayed the growth rate of  the
artemisinin-resistant field isolate alongside the revertant counterpart over 18 days in
8 µM isoleucine. The low isoleucine treatment increased the doubling time of  both
isolates, however, the growth rate of  artemisinin-resistant isolate remained notably
higher than the revertant (Figure 2.12B). When the growth rate of  the two parasite
genotypes in both forms of  media was analyzed in a multifactor regression, no geno-
type by media interaction was detected (ie: the difference in growth rate between two




Together, these data show that the single amino acid change in the K13 gene that
confers artemisinin-resistance also confers an increased rate of  growth. It is not clear
whether this growth is due to faster progression through the cell cycle, production
of  increased merozoite numbers, or a combination of  several factors. The fact that
Pf PI3K inhibition retards cell cycle progression (Figure 2.11), and that artemisinin-
resistant K13 mutants have higher Pf PI3K levels (Mbengue et al., 2015), suggests that
the incraesed growth rate may be due to faster progression through the cell cycle as
a result of  increased Pf PI3K activity.
Artemisinin-resistance confers increased recovery upon isoleucine starvation
and extends the G1 phase of the cell cycle
We next evaluated the response of  the artemisinin-resistant K13 mutant and its re-
vertant to prolonged incubation in the complete absence of  extracellular isoleucine.
As done earlier with NF54 parasites (Figure 2.2), young rings of  the artemisinin-
resistant isolate and the revertant parasites were washed repeatedly then transferred
to isoleucine-lacking culture medium to induce dormancy-like slow growth. After
72 h of  starvation, isoleucine was added back to the medium and the parasites were
cultured for an additional 72 h of  recovery. The artemisinin-resistant mutant dis-
played robust recovery from starvation (Figure 2.13A), as expected from our earlier
experiments with our NF54 clone (Figure 2.2), and the initial report using a 3D7 line
(Babbitt et al., 2012). Surprisingly, the revertant line was not able to recover from
the growth retardation induced by prolonged isoleucine starvation, displaying a fi-
nal parasitemia of  only 60% of  its starting parasitemia after recovery. The genetic
background of  this parasite isolate must differ from NF54 and 3D7 in a manner that
renders it vulnerable to prolonged amino acid starvation. However, the change of
a single amino acid in the K13 gene reverses this effect, allowing the parasite to re-
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cover from isoleucine induced growth retardation. The fact that this same mutation
also allows the parasite to recover from the growth retarding effects of  artemisinin
derivatives, further suggests a common underlying mechanism of  growth regulation.
In a transcriptomic study of  (non-syngenic) artemisinin-resistant and sensitive
field isolates, Mok et al. observed that artemisinin-resistant isolates appeared to have
an extended G1 phase of  the cell cycle relative to sensitive isolates when grown in
normal culture medium in vitro (Mok et al., 2015). This finding seems to be at odds
with our observation that the artemisinin-resistant line displays an increased rate of
growth. However, when we measured the DNA content of  the K13 mutant and the
revertant line after 72 h of  isoleucine starvation, the artemisinin-sensitive revertant
displayed a much higher proportion of  cells with greater than 1C DNA content (Fig-
ure 2.13B and C). This suggests that the artemisinin-resistant mutant is taking longer
to reach S-phase during isoleucine-starvation induced slow growth. This could be
explained either by to the resistant mutant having a slower overall growth rate, which
is contradicted by our observations in both normal and low isoleucine media (Fig-
ure 2.12), or by an extended G1 phase, as suggested by Mok et al. (Mok et al., 2015).
Artemisinin is least effective during ring stages of  G1 prior to the onset of  hemoglobin
digestion (Klonis et al., 2013). An extension of  G1 could potentially contribute to
the resistance phenotype by increasing the amount of  time the parasite remains in its
least vulnerable state. It is not clear how or if  this extension of  G1 contributes to





In S. cerevisiae, transition into quiescence upon nutrient limitation has longed served
as a model for cellular dormancy. When one of  a number of  nutrients is exhausted,
yeast appears to reversibly arrest transit through the cell cycle prior to DNA replica-
tion, and enter a state of  low metabolic activity in which the cells can remain viable
for an extended period of  time (“G0”). Transcriptomic profiling of  yeast batch cul-
tures as they enter stationary phase quiescence demonstrated a progressive slowing
of  growth as nutrients were exhausted and the eventual induction of  a stress response
trancriptional program as dormancy was established (Saldanha et al., 2004). With the
exception of  a stress response trancriptional program, many of  these characteristics
of  yeast quiescence fit those observed by Babbit et al. in their initial description of
the P. falciparum response to isoleucine starvation namely, initial transcriptomic slow-
ing of  the cell cycle, apparent arrest prior to DNA synthesis, decreased metabolic
activity, and maintenance of  viability over extended starvation. However, more re-
cent studies of  the yeast quiescence response using modern genomic tools and gene
knockout collections have complicated, instead of  clarified, the understanding of  this
response. Studies have shown that the stress adaptations and metabolic changes once
thought to be unique to the G0 state can be induced in other phases of  the cell cycle
(Laporte et al., 2011). Furthermore, experiments controlling yeast growth by nu-
trient limitation in chemostat culture demonstrated that the higher the growth rate
was limitation, the longer cells spent in G1 of  the cell cycle, and the more the tran-
scriptomic profiles resembled those of  quiescent cells in stationary phase attained in
batch cultures (Brauer et al., 2008). Combined, these data suggest that dormancy or
quiescence in yeast may not be due to a unified differentiation program, but instead,
an extreme slowing of  the cell cycle with a coincident induction of  metabolic and
transcriptional stress responses. Our study of  the P. falciparum response to isoleucine
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starvation suggest a similar conclusion.
We repeated the isoleucine starvation protocol described by Babbitt et al. using
an NF54 clone of Plasmodium falciparum. Over the short term, the parasites appeared
to slow progression through the cell cycle and remain in G1, as Babbitt et al. had
described. However, when tracked for extended periods, it became clear that the
parasite continued through the cell cycle, completing schizogeny and reinvading, at
a slow pace. Despite some death over the course of  starvation, upon addition of
isoleucine the slow growing parasites readily recovered and resumed normal growth.
P. falciparum does not appear to enter a programmed state of  dormancy during the
asexual cycle upon amino acid starvation. Nonetheless, the ability to attenuate and
resume growth is likely advantageous in vivo, where the parasite can experience tran-
sient periods of  low isoleucine in malnourished human hosts (Baertl et al., 1974).
It is not clear how the parasite is able to continue the cell cycle without a
source of  extracellular isoleucine. Some isoleucine may be reclaimed from exist-
ing cellular proteins through autophagy or proteasomal degradation, but it seems
unlikely that this would be sufficient to support completion of  the cell cycle. A
more likely source would be the small amount of  other erythrocyte proteins im-
ported and degraded along with hemoglobin. If  this were the case, it may explain
why the artemisinin-sensitive revertant line was unable to survive prolonged amino
acid starvation. Chloroquine resistance genes are at or near fixation throughout the
regions in which artemisinin resistance has emerged (Muhamad et al., 2011). The
chloroquine resistance mutations in the Pf CRT gene cause digestion defects in the
parasite’s digestive vacuole, and parasites carrying the mutations have been shown
to be much more reliant on extracellular amino acids (in addition to isoleucine) for
normal growth (Lewis et al., 2014). Thus, the artemisinin-sensitive revertant line may
suffer from greater isoleucine starvation than chloroquine sensitive parasites (such as
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the NF54 clone used throughout this study) do to its vacuolar digestion defect. This
question could be addressed by testing syngenic parasite lines that only differ in their
chloroquine resistance alleles (Sidhu et al., 2002).
Babbitt et al. concluded from their observations of  dormancy-like state that
the regulation of  cell cycle progression in P. falciparum is a passive process, deter-
mined mainly through limiting reaction rates, with isoleucine starvation decreasing
translational processivity, and thereby arresting growth (Babbitt et al., 2012). Simi-
lar conclusions were drawn from similar observations in yeast, until the genetic fac-
tors responsible for nutrient-dependent growth rate modulation, namely the TORC1
pathway, were discovered (Loewith and Hall, 2011). Several pieces of  evidence con-
tradict interpretation of  passive growth regulation. We found that the K13 revertant
clone is less capable of  surviving prolonged isoleucine starvation than its syngenic
artemisinin-resistant counterpart. If  growth retardation were due to translational
stalling in the absence of  isoleucine-charged tRNA, it would be expected to effect
all parasite genotypes equally. Furthermore, several Plasmodium falciparum-specific in-
hibitors of  tRNA-synthetases and translation initiation factors have been described
(Herman et al., 2015)(Hoepfner et al., 2012)(Baragaña et al., 2015). All are potently
lethal, and none produces a dormancy-like state like that observed from isoleucine
starvation. Perhaps the most intriguing evidence to suggest that growth rate regula-
tion in the parasite is an active process, however, is our observation that cells become
refractory to isoleucine removal once DNA synthesis commences. This suggests, like
in other organisms, the parasite is able to sense and respond to its environment in
G1, but ignores this sensing mechanism once the mitotic cycle initiated.
Yeast deprived of  nitrogen, phosphate, glucose, or any of  several other nutrients
during early G1 phase will slow growth and enter the quiescence program described
above. If  the nutrient is removed after a specific point late in G1, however, the cell
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proceeds with S-phase and mitosis, then enters the quiescent state in the subsequent
generation (Hartwell, 1974). A similar process occurs in yeast for differentiation into
budding cells when stimulated with mating factor (Hartwell et al., 1974), and an anal-
ogous phenomenon exist in mammalian cells starved of  growth factors or amino
acids (Pardee, 1974)(Saqcena et al., 2013). The point at which these cells “decide” to
arrest growth or continue with mitosis is known as a G1 checkpoint. We observed
that P. falciparum will enter dormancy-like slow growth when deprived of  isoleucine
in G1, but continues on with DNA-replication and schizogeny if  isoleucine is re-
moved after S-phase has commenced (at approximately ~30 hpi). This phenomenon
follows the same behvior as the G1 checkpoints in yeast and mammalian cells. In
those systems, the G1 checkpoint is determined through the interaction of  cyclins
and cyclin-dependent kinases (CDKs) which activate a positive feedback loop of  S-
phase transcription factors to irreversibly drive the cell cycle forward. The isoleucine
refractory point we have observed in Plasmodium falciparum may follow a similar mech-
anism, however, we have no means of  verifying it at present. The P. falciparum genome
encodes three or four putative cyclins and five kinases of  the CDK family, all of  which
display periodic expression profiles across the intra-erythrocytic cycle. Two CDKs
(PF3D7_1014400, PF3D7_1014400), and a single cyclin (PF3D7_1463700), display
changes from high expression in G1 to low expression in schizogeny with an inflec-
tion point at roughly 30 h post invasion (Bozdech et al., 2003), making them potential
candidates as regulators of  the G1/S transition. It would be interesting to investigate
if  manipulating the expression or stabiltity of  these candidate proteins affects the
timing of  the isoleucine refractory point and entrance into S-phase.
Once the isoleucine refractory point is passed, the parasite is able to complete
schizogeny, generating upwards of  twenty or more merozoites, without a source of
isoleucine. In their study, Babbitt et al. demonstrated that parasites maintained in low
isoleucine media were no less capable of  surviving isoleucine starvation than those
39
2-36
maintained in high isoleucine media, and that parasites instantly responded to the
removal or readdition of  isoleucine by phosphorylating IF2α (Babbitt et al., 2012).
Together, these data suggest that it is unlikely that the parasite maintains an accessible
intracellular pool of  isoleucine. However, yeast starved of  nitrogen (required for
amino acid synthesis) after the G1 checkpoint are similarly capable of  undergoing
S-phase and mitosis without an amino acid supply (Hartwell, 1974). The parasite, as
well as yeast, may simply recycle existing proteins or produce the minimum proteome
necessary in advance of  the G1-S checkpoint to sustain completion of  the cell cycle.
In yeast, G1 is the phase of  the cell cycle at which cellular size (i.e. volume and
mass) is determined. Yeast cells in which the G1 phase has been artificially lengthened
can attain much larger sizes than controls by the time they reach the G1 checkpoint
(Popolo et al., 1982). Extension of  the G1 ring and trophozoite stages of P. falci-
parum have a similar effect in establishing the size and nutrient content of  the parasite
at the onset of  S-phase. It is well established that certain parasite isolates produce
greater numbers of  merozoites than others (Reilly et al., 2007). Perhaps an elon-
gated G1 phase allows increased nutrient acquisition for merozoite production during
schizogeny. This would explain the apparent discrepancy we observed between the
growth rate and G1 length of  the K13 mutant isolate and its revertant. Perhaps the
mutant is able to produce more merozoites per cycle due to its prolonged G1 phase,
thereby increasing its effective growth rate.
Early studies of  both artemisinin resistance and isoleucine-starvation led authors
to put forth similar theories of  dormancy-like strategies employed by the parasite to
survive these seemingly different forms of  stress. Our present observations, along
with more recent studies by others of  artemisinin survival in field isolates, suggest a
different model. However, there is reason to suspect recovery from both treatments
involves overlapping molecular mechanisms. Figure 2.14 summarizes the similarities
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between recent findings in the artemisinin-resistance literature and observations gen-
erated in this study. Central to both responses is the observation that the treatments
induce a retardation of  parasite growth, and do not activate a programed differen-
tiation into a dormant state. Surviving parasites are able to endure growth retar-
dation and resume normal growth. Artemisinin-susceptible parasites cannot. The
same single amino acid change in the K13 gene that renders parasites capable of  re-
covery from artemisinin treatment also confers increased recovery from prolonged
isoleucine starvation.
It is not yet understood how artemisinin and its derivatives induce growth retar-
dation. However, artemisinin has been reported to be a direct inhibitor of Pf PI3K
(Mbengue et al., 2015), and we have demonstrated that a PI3K inhibitor unrelated to
artemisinin is capable of  inducing growth retardation similar to that observed upon
isoleucine starvation. Likewise, artemisinin-resistant parasites carrying K13 muta-
tions have been reported to have higher intracellular levels and activity of Pf PI3K
(Mbengue et al., 2015), and we have found that one such mutant displays an in-
creased growth rate in normal or low isoleucine media, further implicating Pf PI3K
activity and regulating parasite growth. The mechanism by which Pf PI3K would
regulate growth is unknown. In mammalian cells, the human ortholog (HsVps34)
has been implicated in detection of  amino acids upstream of  mTOR in the TORC1
pathway, the central nutrient and growth signalling pathway in eukaryotes (Gulati et
al., 2008)(Munson et al., 2015)(Yoon et al., 2011)(Nobukuni et al., 2005)(Byfield et
al., 2005)(Yan et al., 2009). As discussed in the ensuing chapter, the TORC1 pathway
has been largely lost in Apicomplexa, though we report evidence that at least one other
residual component of  TORC1 is needed for P. falciparum to recover from prolonged
isoleucine starvation. Pf PI3K may regulate parasite growth by activating a reduced,




An alternative possibility is that Pf PI3K regulates growth by directly affecting
the acquisition of  amino acids. In other eukaryotes, Class III PI3K kinases play a cen-
tral role in vesicular trafficking, including coordinating the trafficking of  endocytotic
and phagocytotic vesicles (Backer, 2008). Plasmodium falciparum imports hemoglobin
from the host cell through an analogous mechanism, and Pf PI3K inhibition by Wort-
manin or LY294002 has been shown to inhibit the import process (Vaid et al., 2010).
Additionally, Pf PI3K inhibitors are more potent when applied to cultures in media
containing isoleucine as the only extracellular amino acid, presumably because block-
ing hemoglobin import renders extracellular amino acids the only remaining source
(Vaid et al., 2010). Two independent studies have reported that artemisinin also in-
hibits hemoglobin endocytosis in Plasmodium falciparum (Hoppe et al., 2004) (Klonis
et al., 2011). Thus, artemisinin may block hemoglobin import through Pf PI3K inhi-
bition, and effectively cause the same amino acid starvation-induced slow growth as
extracellular isoleucine withdrawal.
There is further circumstantial evidence suggesting that artemisinin may inhibit
hemoglobin import and amino acid acquisition in early stage parasites. As mentioned
earlier, chloroquine resistance causes digestion defects and increases the reliance on
extracellular amino acids. When an artemisinin-resistance allele was introduced into a
3D7 (chloroquine sensitive) genetic background, the transgenic line displayed higher
levels of  artemisinin resistance than when introduced into a Dd2 (chloroquine re-
sistant) background (Ghorbal et al., 2014)(Straimer et al., 2015). If  the K13 muta-
tions conferring artemisinin resistance lead to increased hemoglobin import through
Pf PI3K elevation, it may partially overcome the fitness load of  the chloroquine sen-
sitive allele. In support of  this, we found that the artemisinin resistant lines display
higher growth rates in both normal and low isoleucine media, suggesting the single
amino acid change that confers artemisinin resistance also confers a fitness advantage








The NF54 clone used for most experiments was produced by and obtained from
the lab of  David A. Fidock at Columbia University (Adjalley et al., 2011). The The
Hsp101-DD conditional PTEX export 3D7 clone was produced by and obtained
from the lab of  Dan Goldberg at Washington University (Beck et al., 2014). The
K13 R539T artemisinin resistant isolate (Cam3.I IPC 5202) was isolated from a pa-
tient Battambang province, Cambodia, in 2011. It was obtained from the Malaria
Research and Reference Reagent Resource Center (MR4) for distribution by BEI Re-
sources NIAID, NIH, product number MRA-1240, and originally contributed by Di-
dier Ménard. The corresponding revertant line, Cam3.I_rev, was also obtained from
the BEI resources NIAID, NIH, product number MRA-1252, and was contributed
by David A. Fidock (Straimer et al., 2015).
Parasite Culture and Media
Parasites were cultured using standard methods (Jensen and Trager, 1977) in flasks
gassed with a mixture of  90% N2, 5% CO2, 5% O2 (Airgas, #Z03NI9022000033).
Normal culture medium consisted of  RPMI 1640 with L-glutamine and 25 mM
HEPES (Corning, #10-041-CV), with 5.0g/L Albumax II Lipid-Rich BSA (Ther-
moFisher Scientific, #11021029), 3.7mM Hypoxanthine, and 50µg/mL gentamicin.
The Isoleucine deficient medium consisted of  10.3g/L RPMI 1640 Ile-Dropout
medium (US Biologicals, #R9014), supplemented with 2.0g/L NaHCO3, 6.0g/L
HEPES, 5.0g/L Alubmax II, 3.7mM Hypoxanthine, and 50µg/mL gentamicin.
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The 8µM Isoleucine medium was the same as the Isoleucine medium, except was
supplmented with 8µM L-Isoleucine. Trimethoprim was obtained from Sigma
Aldrich (#T7883), and used at a final concentration of  10µM. The PI3K inhibitor
LY294002 was obtained from Cell Signaling Technology (#9901) and used at a final
concentration of  100µM.
Flow Cytometry
For each sample to be analyzed, 1mL of  parasite culture was pelleted and resuspended
in 1mL of  PBS containing 4%w/v paraformaldehyde. Samples were rocked at 4oC for
20-30h of  fixation. Samples were then pelleted and resuspended in PBS containing
0.1% v/v Triton-X 100 and rocked at room temperature for 1h for permeabilization.
This process was then repeated three additional times with PBS (without Triton-X
100) to remove as much hemoglobin as possible. Samples were then diluted approx-
imately 100-fold into normal culture medium containing 1x SYBR Green I (Ther-
moFisher Scientific, #S7563) and analyzed on a FACSCalibur (BD Biosciences) flow
cytometer. The resulting data was further analyzed using FLOWJO 10.0.7 analysis
software.
Growth Curves
Asynchronous parasite cultures were maintained under the conditions described and
sampled every 48h to quantify parasitemia by flow cytometry. Cultures were then di-
luted between 2 and 10-fold to maintain a parasitemia between 0.5-1.0% parasitemia
and the dilution factor was recorded. The growth at each time point was measured
as the parasitemia multiplied by the dilution factor of  the previous dilution. The fi-
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nal dataset was normalized such that the initial parasitemia for each line started at
1.0 to account for differences in the starting parasitemias of  the different parasite
lines. A multi-factor regression of ln(adjusted parasitemia) ∼ hour + genotype +
media + media*genotype was fit to determine the potential effects of  genotype (i.e.:
artemisinin-resistance), isoleucine level in media, and potential interactions between
isoleucine level and genotype while treating time as a covariate. Doubling time (tD)
was calculated for each clone from single factor regressions against time alone, using
tD = log(2)/βo, where βo is the coefficient from the single factor regression.
Statistical Analysis
All statiscal analyses were performed using R version 3.2.3 (2015-12-10)(R Core
Team, 2015). T-tests, linear and logistic regressions, and some figures were gen-
erated using R base functions. The drc package (Ritz, C. and Streibig, J.C., 2005) was
used for determining the 50% effect points of  logistic models, and the ggplot2 package




Plasmodium falciparum Maf1, a relic of the





The TORC1 pathway is a highly conserved signaling pathway across eukaryotes that
responds to nutrient and stress signals to regulate the cellular rate of  growth as well
as the transition into and maintenance of  dormancy. The majority of  the path-
way’s components, including the central TOR kinase, have been lost in the Api-
complexan lineage. Plasmodium falciparum has retained a few peripheral components,
including a putative ortholog of  the TOR-regulated RNA Polymerase III repressor
Maf1. Here, we confirm Pf Maf1 can functionally complement its well-described
yeast counterpart, and investigate its role in regulating RNA Pol III expression under
conditions of  nutrient starvation and other stresses. Using a transposon-insertion
mutant with an altered Maf1 expression profile, we demonstrate that proper Maf1
expression is necessary for survival of  the dormancy-like state induced by prolonged
amino acid starvation, and needed for full recovery from other stresses that slow
or stall the parasite cell cycle. The Maf1 mutant is defective in the down-regulation
of  pre-tRNA synthesis under nutrient-limiting condtions, indicating Maf1’s function
as a stress-responsive regulator of  structural RNA transcription is conserved in P.
falciparum. Lastly, recent work has implicated other peripheral components of  the
TORC1 pathway in artemisinin resistance, and has demonstrated that parasites car-
rying artemisinin-resistant K13 alleles display an enhanced ability to recover from
drug-induced growth retardation. We show that one such artemisinin-resistant line
displays greater regulation of  pre-tRNA expression, and higher levels of  survival
upon prolonged amino acid starvation, suggesting that the same residual TORC1-





Efficacy of  the frontline antimalarial artemisinin is decreasing throughout Cambodia
and other parts of  Southeast Asia (Ashley et al., 2014). The drug resistance phenotype
presents as a persistence, or delayed clearance, of  ring-stage parasites in the peripheral
blood at times post-treatment after susceptible parasites would have been cleared
(Dondorp et al., 2009). Early theories derived from in vitro studies of  susceptible
parasites treated with drug proposed the so-called Sleeping Beauty hypothesis:ring-stage
resistant parasites enter a state of  dormancy, arresting the cell cycle and decreasing
metabolic activity to limit damage, then resume growth after drug concentrations
have decayed below effective levels (Kyle DE, Webster HK, 1996)(Hoshen et al.,
2000)(Teuscher et al., 2010)(Witkowski et al., 2010)(Codd et al., 2011) (Cheng et al.,
2012). However, more recent work using field isolates known to carry mutations
conferring the delayed clearance phenotype has cast doubt on the model of  a full cell
cycle arrest and transition to dormancy. Instead, studies suggest that artemisinin and
its derivatives induce a transient slowing of  the cell cycle (Klonis et al., 2011), and that
parasites carrying resistance-conferring mutations are able to survive this retardation
and resume growth, while susceptible parasites are not (Dogovski et al., 2015). The
mechanism by which the drug transiently slows the cell cycle or how the resistant
alleles allow for recovery remain unclear.
The yeast Saccharomyces cerevisiae has long been a model for the induction and
maintenance of  dormancy. When nutrients are depleted in the stationary phase of
growth, cells appear to cease cycling through the mitotic cycle and enter a state of  low
metabolic and translational activity. This state serves a protective function as yeast
deprived of  carbohydrates can remain viable and recover after more than one hundred
days of  starvation (Lillie and Pringle, 1980). However, the distinction between slow
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growth and full cell cycle arrest has been brought into question (Daignan-Fornier and
Sagot, 2011). As nutrients decline, the yeast cell cycle progressively slows (Brauer et
al., 2008), leading some authors to suggest that stationary-phase dormancy may not
be a distinct state of  differentiation, but simply an “extreme manifestation of  slow
growth” (Daignan-Fornier and Sagot, 2011). As discussed below, the same pathway
that governs the rate of  progression through the cell cycle also regulates the transition
into stationary phase and longterm survival in that state, suggesting that if  dormancy
and growth-retardation are not manifestations of  the same process, their regulation,
at a minimum, overlaps.
Asexual stages of  the Plasmodium falciparum enter a state reminiscent of  the yeast
stationary phase upon nutrient limitation in vitro. When deprived of  extracellular
isoleucine, the only amino acid that cannot be obtained from the digestion of
hemoglobin, the parasite dramatically slows its cell cycle and exhibits decreased
translational and metabolic activity (Babbitt et al., 2012). The parasite can remain
in this state for several days and resume normal growth upon isoleucine resup-
plementation with little loss in viability (Babbitt et al., 2012). Given the overlap
between growth-regulation and long term nutrient starvation in yeast, there is
reason to believe that there may be overlap in the pathways that govern the ability
of P. falciparum to recover from long-term isoleucine starvation and the ability of
artemisinin-resistant parasites to recover from drug-induced growth retardation.
A likely candidate to govern these responses is the TOR Complex 1 (TORC1)
pathway, as it is known to integrate a range of  positive and negative growth signals,
most notably the presence of  amino acids, to drive or inhibit cellular growth (Loe-
with and Hall, 2011). The TORC1 pathway is highly conserved throughout eukary-
otes, and was likely a central signaling hub in the last eukaryote common ancestor
(Serfontein et al., 2010)(van Dam et al., 2011). In mammalian cells in culture, in-
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hibition of  mTOR with the drug rapamycin induces G1 arrest in certain cell types,
but only slows cell cycle progression in others (Abraham and Wiederrecht, 1996). In
yeast, complete chemical or genetic inhibition of  TOR drives cells into dormancy or
quiescence (Barbet et al., 1996), while partial inhibition slows cell cycle progression
(Powers et al., 2006). Additionally, in yeast, TORC1 components were found to be
the top hits in a genome wide screen for the ability to maintain viability in stationary
phase during prolonged starvation (Powers et al., 2006).
However, the majority of  the most familiar components of  the TORC1 path-
way, notably the TOR kinase itself, have been lost through genomic reduction in
the evolution of  the Apicomplexan lineage (Figure 3.1) (Serfontein et al., 2010) (van
Dam et al., 2011). P. falciparum retains only a few peripheral orthologs. Intriguingly,
two such components were recently associated with artemisinin resistance in para-
sites carrying K13-resistance alleles. Increased levels and activity of  both Pf PI3K
and Pf PKB (also known as Pf Akt) were demonstrated to confer increased survival
to dihydroartemisinin (DHA) treatment in vitro (Mbengue et al., 2015), suggesting
these remnants of  a TORC1-like pathway may actively regulate the slow growth and
recovery program required to survive artemisinin treatment.
Pf PI3K (PF3D7_0515300) is the Plasmodium ortholog of  the Class III phos-
phoinositide 3-kinase PI3K. While several studies have implicated a direct role for
mammalian PI3K (HsVps34) in amino acid sensing and TOR signaling (Nobukuni
et al., 2005)(Byfield et al., 2005)(Gulati et al., 2008)(Yan et al., 2009)(Yoon et al.,
2011), it is normally associated with functions in vesicular trafficking, phagocytosis,
endocytosis, and coordination of  autophagosome formation in autophagy (Backer,
2008); processes that can contribute to the intracellular amino acid supply through
both anabolism and catabolism. In P. falciparum, Pf PI3K is involved in endocyto-





hemoglobin uptake and causes growth-retardation (Vaid et al., 2010)(Chapter 2). A
recent study reported that PI3K is the mechanistic target of  artemisinin in Plasmod-
ium ring stages, and that increased intracellular levels of  PI3K confer resistance to
the drug (Mbengue et al., 2015). Conceivably, inhibtion of  PI3K by artemisinin may
slow growth by decreasing intracelluar amino acid levels via blockage of  hemoglobin
import, or may inhibit some unknown PI3K-mediated signaling.
The TORC1 complex exerts its growth-regulating effects by phosphorylating
a range of  downstream products. The kinase S6K is one such target, which in turn
phosphorylates a cascade of  downstream pro-growth substrates, such as the riboso-
mal protein S6, to increase cellular translational output (Tavares et al., 2015). Human
S6K is part of  a paralog family consisting of  S6K, SGK, RSK, and PKB (also known
as Akt), which expanded from a single origin in the last eukaryote common ancestor
(van Dam et al., 2011). P. falciparum encodes a single homolog of  this kinase family
(PF3D7_1246900), which has previously been referred to as Pf PKB or Pf Akt (af-
ter the mammalian upstream TORC1 regulator) (Vaid and Sharma, 2006) (Mbengue
et al., 2015), but the protein lacks the Pleckstrin Homology (PH) domain that dis-
tinguishes Akt form other family members, and the parasite does not encode the
Class I PI3K and PDK1 enzymes that regulate human Akt activity. When Plasmodium
falciparum cells are treated with artemisinin-derivatives, Pf PKB activity is inhibited
(Mbengue et al., 2015), reminiscent of  the of  manner in which the mammalian or
yeast orthologs, S6K and Sch9, are inhibited upon amino acid starvation or of  treat-
ments that inhibit or retard growth (Urban et al., 2007)(Tavares et al., 2015). Over-
expression of Pf PKB in an artemisinin sensitive genetic background causes parasites
to recover from DHA-treatment at levels comparable to artemisinin-resistant field
isolates (Mbengue et al., 2015), suggesting increased Pf PKB activity may contribute
to recovery from artemisinin induced growth-retardation.
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A more recently appreciated downstream effector of  the TORC1 pathway is
the RNA Polymerase III regulator Maf1. Under nutrient replete conditions, TOR
signaling keeps Maf1 phosphorylated and inactive. In human cells, Maf1 appears to
be directly phosphorylated by the TOR kinase (Shor et al., 2010)(Kantidakis et al.,
2010), but in yeast, phorphorylation is performed by the S6K family member Sch9
(Huber et al., 2009)(Lee et al., 2009). Upon starvation, inhibition of  TORC1 leads
to Maf1 dephosphorylation, allowing it to bind to the RNA Pol III holoenzyme,
shutting down Pol III-dependent transcription of  tRNAs, the 5S rRNA, and other
structural RNAs (Pluta et al., 2001)(Vannini et al., 2010). Yeast null mutants of  Maf1
die under nutrient limitation and other factors that inhibit TORC1 due to their in-
ability to regulate Pol III transcription under stress (Upadhya et al., 2002)(Roberts et
al., 2006)(Ciesla et al., 2007)(Huber et al., 2009). In yeast, Maf1 is one of  the most
important genes for maintaining viability during long term starvation in stationary
phase (Powers et al., 2006)(Cai and Wei, 2015). A putative Maf1 ortholog appears to
be conserved in the Plasmodium genus.
Here, we demonstrate that this gene is a functional ortholog of  the yeast Maf1.
A transposon-insertion line of P. falciparum with defective Maf1 expression is unable
to regulate Pol III activity and maintain viability in the dormancy-like state induced
by isoleucine starvation. This mutant displays additional growth and recovery defects
for a range of  growth-inhibiting forms of  stress. Furthermore, an artemisin-resistant
isolate displays increased Pol III regulation and survival upon amino acid starvation,
potentially connecting Pf Maf1, Pf PKB, and Pf PI3K into a simplified, yet still func-
tional, TORC1 pathway capable of  regulating parasite growth in the presence of  nu-




PF3D7_0416500 is a functional ortholog of Maf1
The Plasmodium falciparum gene PF3D7_0416500 encodes a putative ortholog of
Maf1. As with many P. falciparum proteins, the P. falciparum ortholog contains a large,
asparagine-rich low-complexitiy region near the N-terminus accounting for 200/389
(51%) amino acids of  the sequence. This region is not conserved in other Plasmodium
species, and when this region is not considered, the P. falciparum sequence aligns well
with the region of  the human ortholog used in determining the crystal structure
(PDB: 3NR5) (Vannini et al., 2010), and with the corresponding regions of  the S.
cerevisiae and S. pombe proteins (Figure 3.2).
In yeast, Maf1 knockout cells display severe growth defects and death when
grown on a non-fermentable carbon source or when treated with the TOR pathway
inhibitor rapamycin (Roberts et al., 2006). To test whether the P. falciparum gene is
a true functional ortholog of  Maf1, we attempted to complement this phenotype in
yeast. Maf1 is regulated by phosphorylation in both yeast and human cells, however,
the regions in which the phosphorylation occurs are the least conserved regions of
the protein sequence. In yeast, phosphorylation has been described in two regions,
the “mobile insertion” near the N-terminus (so-named for its sensitivity to limited
proteolysis in recombinant proteins), and the “acidic tail” at the c-terminus (the c-
terminus of  all Maf1 orthologs, including Pf, have a high D and E content, but oth-
erwise show little sequence identity) (Vannini et al., 2010). In order to account for
these phospho-regulatory regions, we generated a chimeric Maf1 sequence consisting
of  the yeast N-terminus and mobile insertion, the Pf Maf1 central core, and the yeast




falciparum sequence, the region used spans 67% of  the human ortholog’s core region
used in producing the crystal sructure (Vannini et al., 2010).
When grown on medium containing 10 nM Rapamycin, wild type yeast cells
were able to grow but Maf1-knockout cells were not (Figure 3.3). When either the
full-length yeast protein or the yeast-P. falciparum chimera was expressed from an epi-
somal plasmid, partial growth was restored, indicating that the core region of  the P.
falciparum ortholog is capable to functionally complementing the yeast knockout cells.
The PB-11 parasite clone carries a transposon insertion upstream of the Maf1
open reading frame
We attempted to disrupt the Maf1 ortholog PF3D7_0416500 with several different
plasmids for single and double cross-over recombination, including multiple attempts
using CRISPR-Cas9/guide-RNA. None of  our efforts was successful, raising the pos-
sibility that this gene is essential for intraerythrocytic growth. We were not successful
in integrating any C-terminal epitope tags or destabilization-domains either, and no
3’ integration was ever detected by PCR in transfected parasites, suggesting an un-
modified C-terminus may be necessary for proper function.
Surprisingly, we were also unable to express ectopic copies of  Maf1 in wild
type parasites, either using episomal plasmids or chromosomal-integration using the
attB/attP system (Nkrumah et al., 2006). We attempted both N-terminal and C-
terminal tags, as well as both strong (eEF1α) (Talman et al., 2010) and weak (mRPL2)
(Balabaskaran Nina et al., 2011) promoters, but no stable transfectants could be ob-
tained. Unrelated control plasmids routinely produced stable transfectants. Only a
single ectopic expression construct produced stable parasites, and it consisted of  the




lization domain (de Azevedo et al., 2012) expressed from the weak mRPL2 promoter.
The resulting line expressed the Maf1 transgene well below endogenous levels and
was unresponsive to protein stabilization with the ligand Shield, limiting its utility in
any further analyses (Figure 3.4). These failed efforts suggests Maf1 may be toxic to
cells if  expressed at the wrong time and/or level.
In their efforts to generate a piggyBac mutant collection, Balu et al. generated a
Maf1 transposon-insertion mutant in an NF54 clone background (Balu et al., 2009).
In this clone, identified as PB-11, Balu et al. reported the piggyBac transposon to be
inserted at the TTAA sequence ending at position +8 of  the open reading frame,
which should disrupt the coding sequence to generate a genetic knockout (Figure
3.5).
We obtained this mutant and discovered that the insertion site had been incor-
rectly assigned. Instead of  the +8 position of  the ORF, the insertion is at a TTAA
sequence 53bp upstream of  the start codon. Whole-genome sequencing of  the PB-11
line (Illumina HiSeq paired-end sequencing, 73x coverage), demonstrated extensive
read-coverage for the -53 insertion position, and no support for a +8 insertion site
(Figure 3.6). To rule out the possibility of  additional, unknown piggyBac insertions in
the genome, we aligned one file of  the paired-reads to the transposon sequence and
the mate file to the genome (and vice versa) to see where each transposon-aligning
paired-read mapped (Balu et al., 2013). Paired-ends were found to only to align to
the Maf1 locus or to regions of  the genome used as regulatory sequences within the
transposon itself  (such as the Calmodulin promoter or the HrpII 3’UTR). Addition-
ally, we analyzed the PB-11 genome for SNPs and INDELs within all annotated open
reading frames in the genome, but found none of  significance when compared to the




Figure 3.4: Ectopic expression of PfMaf1 is only attainable using a construct designed to attenuate protein ex-
pression. A) A schematic of the transgene used for transfection. A 3xHA tag followed by a DD24 destabilization domain
was fused to the N-terminus of the Maf1 coding sequence and driven by the weak *mitochondrial Ribosomal Protein 2
(mRPL2) promoter. B) A western blot of schizonts of untransfected NF54 parasites, or Dd2attB stably transfected with the
DD24-Maf1 expression plasmid probed with anti-PbMaf1 antisera. The 3xHA and DD24 tag are expected to add 15kDa
to the PfMaf1 molecular weight. Increasing concentrations of the Shield ligand are expected to increase stability and
abundance of DD24-Maf1, but appear to have no effect.
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Figure 3.5: Schematic of the Maf1 genomic locus and piggyBac insertion in wild type and mutant parasites. Num-
bers below the chromosomal line indicate the reported and verified transposon insertion positions relative to the Maf1 start
codon in the PB-11 piggyBac insertion mutant. Right-angled arrows and numbers above the chromosome line indicate
the 5’-RACE determined transcription start sites in wild type (-93nt) and PB-11 mutant (-395nt) cells. The Maf1 transcript
in the PB-11 mutant arises from within the piggyBac transposon and is likely due to bidirectional promoter activity of the
Calmodulin promoter fragment used for drug selection in the transposon.
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Figure 3.6: Upstream insertion of the piggyBac transposon is supported by whole genome sequencing. Top Cov-
erage depth plots indicating the total numer of reads mapping to each base pair around the two termini of the piggyBac
insertion at the -53 TTAA site upstream of the Maf1 start codon. The maximum read coverage for each end of the transpo-
son is indicated by the axis on the left and right. Bottom Alignment of reads to the termini of the transposon surrounding




The PB-11 mutant displays an altered Maf1 expression profile
The -53 insertion in the PB-11 line does not ablate expression of  Maf1. The Maf1
transcript is detectable in PB-11 throughout the asexual life cycle, but never matches
wild type expression pattern (Figure 3.7 and Figure 3.8). Later in the cell cycle, when
wild type Maf1 mRNA abundance dramatically increases, expression of  mutant Maf1
is only moderate.
The insertion of  a ~3kb transposon 53bp upstream of  a start codon would nor-
mally be expected to disrupt the activity of  the native promoter sequence. Therefore,
we performed 5’RACE on Maf1 mRNA from both wild type and the PB-11 mutant
parasites. In wild type cells, we mapped the transcription start site to 93bp upstream
of  the Maf1 start codon, meaning in PB-11 cells, piggyBac is inserted into the 5’UTR
(Figure 3.5). In PB-11 cells, the Maf1 transcription start site mapped 395bp upstream
of  the start codon, producing a chimeric 5’UTR consisting of  346bp of  the right arm
of  the piggyBac transposon (Figure 3.5). When constructing the transposon (pXL-
BacII-DHFR), Balu et al. used the full intergenic region between the start codons
of  Calmodulin (PF3D7_1434200) and its opposite gene (PF3D7_1434300) to drive
expression of  the hDHFR selectable marker (Balu et al., 2005). It appears this region
has enough enhancer or promoter activity to drive transcription of  the chimeric Maf1
mRNA in PB-11 in the opposite direction of  the hDHFR gene. This promoter has
been previously reported to be bidirectional when used in plasmids (Epp et al., 2008).
Anti-sera raised against full-length Plasmodium berghei Maf1 detected production
of  Maf1 protein in both wild type and mutant cells. Maf1 is a low abundance pro-
tein, and is largely undetectable during the first 24 h of  the life cycle (Figure 3.9A).
By 27.5 h post-invasion, Maf1 is detectable in wild type parasites, but is not yet de-





of  the cell cycle at near wild type levels despite the much lower mRNA expression. A
recent global ribosome profiling study of  the Plasmodium falciparum asexual cycle found
Maf1 to be translated at very low efficiency from rings through schizonts (Caro et
al., 2014). Perhaps the chimeric 5’UTR generated by the piggyBac insertion removes
the cis-acting factors in the native 5’UTR responsible for the observed low transla-
tional efficiency, allowing for protein production from low mRNA levels, albeit with
a notable temporal delay in expression. This endogenous translational control may
explain why we were only able to obtain stable transfected lines when expressing
Maf1 from a construct designed to reduce protein production levels (Figure 3.4).
The piggyBac transposon is well known for its ability to excise cleanly from its
insertion site when remobilized (Woodard and Wilson, 2015). We attempted to use
this property to restore the wild type Maf1 locus in the PB-11 mutant line by excising
piggyBac. While we were able to obtain parasites stably expressing the piggyBac trans-
posase, no excision of  the insertion was detected. Similarly, we attempted to restore
the native locus by “crossing-out” the piggyBac insertion via CRISPR-Cas9 mediated
homologous recombination. We attempted several different strategies with different
guide RNAs, however, all failed to restore the wild type locus.
The PB-11 Maf1 mutant fails to recover from a dormancy-like state
TORC1 is best understood as the central hub from which the pro-growth signaling
cascades are relayed in response to changes in intracellular levels of  amino acids. In
yeast, human cells, and Drosophila grown in normal conditions, TORC1 is active, and
Maf1 is inhibited (Roberts et al., 2006)(Shor et al., 2010)(Marshall et al., 2012). When
these organisms are starved of  amino acids (or TORC1 is inhibited by rapamycin),




serve resources and globally dampen translation. If  this safety mechanism is pre-
vented by deletion or silencing of  Maf1, death or severe growth defects result upon
amino acid starvation.
Over the course of  the asexual cell cycle, Plasmodium falciparum resides within its
host erythrocyte and imports and digests hemoglobin as its primary source of  amino
acids. Human hemoglobin lacks isoleucine, and since the parasite does not have
the capacity to synthesize it itself, it must import isoleucine from the extracellular
environment (ie: serum in vivo or culture medium in vitro). A study of  the nutritional
requirements for P. falciparum found isoleucine to be the only amino acid needed in
the culture medium to sustain growth (Liu et al., 2006).
In an important study, Babbit et al. analyzed the parasite’s response to isoleucine
deprivation (Babbitt et al., 2012). Unlike nutrients such as glucose, which leads to
rapid death when removed, Babbit et al. found that parasites appeared to retard
growth and enter a dormancy-like state of  low metabolic activity upon isoleucine
removal. Upon readdition of  isoleucine, parasite growth resumed seemingly unaf-
fected. Parasites could remain in the absence of  isoleucine for upwards of  several
days and only sustain a minor loss in viability. This is reminiscent of  stationary phase
dormancy observed in yeast, a process for which Maf1 is necessary to maintain via-
bility during prolonged starvation (Powers et al., 2006)(Cai and Wei, 2015).
Babbit et al. were unable to identify any genetic factors responsible for this
phenotype. Neither deletion of  the P. falciparum homolog of  the GCN2 uncharged
tRNA sensor kinase, nor the expression of  a non-phosphorylatable form of  its target,
IF2α, had an effect on surival after isoleucine starvation (Babbitt et al., 2012). Given
the role Maf1 plays in the amino acid starvation response in other organisms, we
investigated how the PB-11 Maf1 mutant responded to isoleucine withdrawal.
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Tightly synchronized young ring-stage wild type and PB-11 mutant parasites
were cultured for 72 hours in either normal culture medium, or medium lacking
isoleucine. As previously reported, parasites in the isoleucine deficient medium
stayed at roughly their starting parasitemia while those in normal medium grew
through ~1.5 cell cycles. No detectable difference was observed between wild type
and PB-11 parasites over this period (Figure 3.10).
We next tested whether the parasites remained viable over the duration of  star-
vation. Young ring-stage parasites of  both wild type and PB-11 incubated in medium
lacking isoleucine for 24 hours recovered robustly when returned to normal culture
medium for a 72-hour recovery period (Figure 3.10). However, when the starvation
period was increased to 48 hours, the PB-11 Maf1 mutant line displayed a notable
decrease in recovery, whereas wild type parasites displayed growth levels similar to
parasites cultured for 72 hours in normal medium. With a 72-hour starvation, PB-11
mutants displayed no recovery at all, while wild type parasites recovered robustly.
Despite not being a full gene-disruption, the alteration of  Maf1 expression in the
PB-11 mutant line appears to prevent the parasites from recovering from prolonged
amino acid starvation. To investigate further, we used flow cytometry to track the
parasitemia of  wild type and PB-11 cultures every 24 hours over nine days (216 h) of
starvation in isoleucine deficient medium (Figure 3.11). Over the full course of  the
nine days, the PB-11 parasitemia decreased at a much faster rate (t1/10 WT = 301 h,
t1/10 PB-11 = 196 h)(Figure 3.12). Over the first 72 h, however, the death rates of
the two lines were nearly identical (t1/10 WT = 390 h, t1/10 PB-11 = 369 h)(Figure
3.12). As a verification, aliquots of  each replicate sample were transferred to normal
medium for three days of  recovery at the 72 h, 144 h, and 216 h points of  starvation
(Figure 3.13). PB-11 displayed no regrowth at any time point, whereas wild type







Our previous analysis of  the Plasmodium falciparum response to isoleucine star-
vation revealed that parasites do not arrest growth upon isoleucine withdrawal, but
instead dramatically slow the cell cycle (Chapter 2). Parasites deposited into isoleucine
deficient medium as young rings take roughly twice as long to complete the cell cycle
(~90 h) as compared to culture in normal medium (~45 h). If  PB-11 Maf1 mutant
cells can fully recover from a 24 h isoleucine starvation but not at all from 72 h star-
vation, this suggests a specific point in the cell cycle is crossed between those two
time points at which the ability to recover is irreversibly compromised, presumably
due to altered Maf1 expression.
To map this point, we initiated a culture of  early-ring PB-11 parasites in
isoleucine deficient medium for a 144-hour incubation (Figure 3.14). Every 8 h, an
aliquot of  the culture was removed and resuspended in normal medium for a 72 h
recovery period. A logistic regression was performed on the relative proportion of
parasites recovering at each time point. The results show a transition in the ability
to recover as the duration of  the starvation period increases. According to the
regression fit to the data, the point of  50% recovery occurs at 43.1 h of  starvation.
Given that the cell-cycle advances at approximately half  the normal pace during
starvation, this corresponds to sometime after 22 h post-invasion, the time point at
which differences in Maf1 mRNA (Figure 3.6), and just prior to difference in Maf1
protein expression (Figure 3.9), are most pronounced.
PB-11 displays growth and recovery defects when exposed to multiple growth-
retarding stressors
In yeast, Maf1 arrests Pol III transcription upon a broad array of  biotic and abi-




extension Maf1, typically regulates progression and arrest of  the cell cycle, we inves-
tigated whether other stressors that stall or retard the cell cycle similar to isoleucine
starvation also cause growth or recovery defects for the PB-11 Maf1 mutant.
The antibiotic Fosmidomycin inhibits isoprenoid biosynthesis in the Plasmodium
apicoplast. Howe et al. previously demonstrated that treatment of  parasites with 5
µM Fosmidomycin causes parasites to seemingly arrest in mid schizogeny (Howe et
al., 2013). Subsequent treament of  cultures with the downstream isoprenoid geranyl-
geraniol liberates the parasites from arrest. We arrested wild type and PB-11 mutant
parasites with 5 µM Fosmidomycin for 72 h then treated them with 5 µM geranyl-
geraniol for a 72-hour regrowth period, and compared relative recovery to controls
treated with both Fosmidomycin and geranylgeraniol simultaneously for 72 h (Figure
3.15). The PB-11 Maf1 mutants displayed a pronounced decrease in recovery relative
to the wild type.
Ring-stage Plasmodium falciparum is capable of  surviving prolonged exposure to
temperatures well below 37 oC. In fact, the culture of P. falciparum at ambient room
temperature has been proposed as a means for routine culture synchronization
(Haynes and Moch, 2002). Presumably, the low temperature slows the cell cycle in
a manner that may also require proper Maf1 expression for survival. We incubated
wild type and PB-11 Maf1 mutant parasites at 18 oC for 72 h and then returned the
cultures to 37 oC for 72 h of  recovery and compared the relative growth to controls
that remained at 37 oC for 72 h (Figure 3.15). Once again, the Maf1 mutant parasite
line displayed notably decreased recovery from low temperature stress relative to
wild type.
The growth rate of  wild type and Maf1 mutant parasites is not notably different
when cultured in normal medium (Figure 3.16). However, when cultured in growth
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Figure 3.15: PB-11 Maf1 mutant parasites display defects in recovery from Fosmidomycin and low temperature
treatment. A) Young ring-stage NF54 (WT) and Maf1 mutant (PB-11) parasites were incubated in the presence of 5 µM
fosmidomycin (fosm.) for 72 h, and then ”recovered” by incubation for a further 72 h in the presence of 5µM fosmidomycin
and 5 µM geranylgeraniol. Growth was measured relative to parasites incubated for 72h in normal medium treated with
vehicle (water). B) Young ring-stage parasites were incubated at 18oC for 72h, and recovered by a 72 h growth at 37oC.
Growth was measured relative to parasites incubated for 72 h at 37 oC.
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limiting concentrations of  isoleucine (8 µM, approximately 2% of  the normal RPMI
1640 concentration) the doubling time of  the PB-11 Maf1 mutant is markedly longer.
A similar phenomenon occurs when the parasites are cultured in normal medium at
the stress-inducing temperature of  39 oC (Figure 3.16). Interestingly, the growth rate
of  both wild type and PB-11 parasites is slowed by culture in medium containing
20% normal RPMI 1640 glucose concentration (ie: 0.4 g/L), but appears to affect
both parasite clones equally (Figure 3.16). This suggests that Maf1 is not part of
a universal stress response but instead is a component of  a specific pathway that
responds to certain growth inhibiting and retarding stressors but not others.
tRNA expression in the PB-11 Maf1 mutant is misregulation upon amino acid
starvation
Maf1 is the only known regulator of  RNA Pol III transcription. When conditions are
unfavorable, Maf1 is activated and binds to the Pol III holoenzyme shutting down
transcription of  tRNAs, the 5s rRNA, and small number of  other structural RNAs.
This action is presumed to save cellular resources in times of  stress and nutrient
limitation, and may also globally reduce translational output by limiting the available
tRNA pool. Presumably, Maf1 performs a similar function in Plasmodium falciparum.
The long half-life of  mature tRNAs makes it difficult to quantify changes in their
steady-state expression levels. Typically, pre-tRNAs, immature pre-cursors contain-
ing 5’ and 3’ transcriptional leader sequences and introns, are quantified instead, as
these species are rapidly processed allowing the assessment of  Pol III transcriptional
activity. At present, no pre-tRNAs sequences have been annotated in the Plasmodium
falciparum genome. Nearly every eukaryote tyrosine tRNA gene contains an intron
immediately 3’ of  the anti-codon, the processing of  which is believed to be necessary
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Figure 3.16: PB-11 Maf1 parasites display a decreased rate of growth in low isoleucine and at elevated temper-
atures. Growth curves were measured for NF54 (WT) or Maf1 mutant (PB-11) parasites cultured in A) normal culture
medium at 37 oC, B) 8 µM isoleucine (approximately 2% the concentration of normal medium), C) normal culture medium
at 39 oC, and D) 20% (0.4 g/L) of the glucose level of normal medium (2.0 g/L). P-values represent a test of parasite line
(i.e: wild type vs PB-11) as a factor in the regression analysis. tD = doubling time.
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for the addition of  the pseudouridine modification found in the anticodon of  all ma-
ture eukaryote tRNATyr (Choffat et al., 1988). We reverse transcribed and cloned the
mature Plasmodium falciparum tRNATyr and found an 11-nucleotide sequence adjacent
to the anticodon was spliced out in the mature tRNA molecule (Figure 3.17). Using
this short intron as a target sequence, we modified a stem-loop RT-qPCR protocol
optimized for microRNAs (Chen et al., 2005)(Varkonyi-Gasic et al., 2007) to quantify
expression of  the pre-tRNATyr while using the similarly sized mature 5.8s rRNA (Pol
I transcript) as reference.
In normal medium conditions, the PB-11 Maf1 mutant parasites display higher
steady-state expression of  pre-tRNATyr (Figure 3.17), suggesting Maf1 may play a role
in regulating tRNA expression in normal growth as well as under conditions of  stress.
After 24 h of  isoleucine deprivation, the difference in pre-tRNATyr levels is even more
pronounced (Figure 3.17), supporting the notion that failure of  the Maf1-dependent
regulation of  tRNA expression contributes to this mutant’s inability to recover from
amino acid starvation and other forms of  stress.
It has been suggested that the increase in intracellular tRNAs levels caused by ge-
netic suppression of  Maf1 can cause a global increase translation due to the increased
levels of  the initiator tRNAiMet (Rideout et al., 2012). Regulating translation under
times of  stress is a fundamental component to most celluar stress responses because
it allows cells to conserve cellular resources, decrease the buildup of  aggregates and
unfolded proteins, and selectively translate specific subsets of  mRNAs (Holcik and
Sonenberg, 2005). If  this process is counteracted by excessive translational initiation,
the cells ability to survive stress may be seriously compromised.
To quantify global translation activity, we used a puromycilation assay (Schmidt
et al., 2009). Briefly, the translation inhibitor puromycin incorporates into nascent
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Figure 3.17: Maf1 mutant parasites display elevated expression of pre-tRNAs under normal and isoleucine-
starvation conditions. A) An alignment of the genomic pre-tRNATyr sequence and the mature tRNATyr reveals an 11-
nucleotide intron adjacent the anticodon. B) Stem-loop RT-qPCR profiling of pre-tRNA expression in NF54 (WT) and
Maf1 mutant (PB-11) parasites. Synchronous young ring-stage parasites were incubated in normal medium or medium
lacking isoleucine for 24 h prior to RNA isolation. Pre-tRNATyr expression was quantified relative to 5.8S rRNA levels.
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peptide chains on actively translating ribosomes. A monoclonal antibody specific
for puromycin can then be used to quantify levels of  puromycin incorporation as
a surrogate for global translational output. We pulsed parasite cultures for 1h with
puromycin prior to harvesting protein, then quantified puromycin incorporation by
ELISA using anti-Pf GAPDH as an internal control.
When cells were cultured in normal medium, the PB-11 Maf1 mutant displayed
moderately higher levels of  puromycin incorporation relative to wild type cells (Figure
3.18). However, after 24 h of  isoleucine starvation, the PB-11 mutant displayed a
dramatic increase in puromycin incorporation relative to the wild type control. This
inability to shutdown translation under amino acid starvation may further contribute
to the mutant line’s inability to survive prolonged starvation.
An artemisinin-resistant K13 variant confers increased survival and greater
control of pre-tRNA expression upon isoleucine starvation
Artemisin and its derivatives induce growth-retardation in ring-stage parasites (Klo-
nis et al., 2011), and artemisin-resistant isolates appear capable of  recovering from
this drug-induced growth inhibition while sensitive isolates cannot (Dogovski et al.,
2015). A recent study reported that increased activity of Pf PI3K and Pf PKB, two
other putative remnants of  the TORC1 pathway in Plasmodium, as the mechanistic ba-
sis for survival in resistant parasites (Mbengue et al., 2015). We investigated whether
this ability to overcome growth-retardation translated to prolonged amino acid star-
vation, and whether drug-resistant parasites displayed differential regulation of  Pol III
transcription as a potential point of  connection between these other TORC1 pathway
remnants and Maf1.





dia (K13 allele: R539T), and a syngenic line in which the K13 was reverted back to
the sensitive allele (Straimer et al., 2015), we cultured the parasites in the absence
of  isoleucine and evaluated their ability to regulate pre-tRNA expression and recover
from starvation (Figure 3.19). After 24 h of  isoleucine starvation, the R539T resistant
isolate displayed 27% the expression level of  pre-tRNATyr observed in the syngenic
revertant line. Consistent with our observation in the PB-11 Maf1 mutant, the ability
to suppress pre-tRNA expression corresponded with an increase in survival. After
72 h of  isoleucine starvation, and a subsequent 72 h of  recovery, the R539T resistant
isolate displayed a relative recovery nearly 3-fold greater than its revertant counterpart
(Figure 3.19).
It should be noted that the revertant, which carries the same K13 allele as the
NF54 “wild type” clone used elsewhere in this study, suffered considerable loss of
viability over the 72 h of  starvation, displaying a final parastemia after recovery of  only
61% of  the starting parasitemia (Figure 3.19). Evidently, the genetic background of
this parasite isolate renders it more vulnerable than typical lab strains (NF54, 3D7)
to isoleucine starvation under the conditions employed here.
Discussion
The TORC1 pathway is a highly conserved signalling pathway that allows eukaryotes
to modulate cellular growth in response to changes in the environement. Most rec-
ognizable components of  this pathway have been lost in the Plasmodium genus. In
this study, we have shown that the Plasmoidum falciparum ortholog of  Maf1, one of  the
few remaining pathway components, contributes to surival and recovery of  parasites
treated to various forms of  growth-inhibiting stress; a phenotype that corresponds
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well with those reported in other organisms.
To study this gene, we made use of  a transposon-insertion mutant produced as
part of  an effort to generate a genome-wide mutant collection. While this mutant was
not a genetic knockout as previously reported, insertion of  the piggyBac element into
the Maf1 5’UTR produced profound changes in both mRNA and protein expres-
sion. Our observation of  the mutant’s inability to regulate pre-tRNA expression and
protein synthesis, a phenotypes previously described for yeast, human, and Drosophila
Maf1 mutants (Roberts et al., 2006)(Shor et al., 2010)(Marshall et al., 2012), sup-
ports the conclusion that the mutant’s altered Maf1 expression profile is responsible
for its inability recover from isoleucine starvation and other forms of  stress. We
were unable to generate a knockout parasite line using standard methods, suggesting
basal Maf1 expression may be essential for in vitro asexual growth. The reason for
why Pf Maf1 would be necessary for growth under normal conditions is not clear, as
Maf1 knockouts are viable in both yeast and mice (Pluta et al., 2001)(Bonhoure et
al., 2015). One possible explanation may stem from the observation that the PB-11
Maf1 mutant displayed elevated levels of  global translation relative to the wild type
control even under normal growth conditions. Plasmodium schizonts are reported to
globally suppress translation at the late stages of  the intraerythrocytic cycle (Zhang
et al., 2012). It is possible that some degree of  Maf1 suppression of  tRNA and the
5S rRNA transcription is needed for the maintaining this suppression.
In yeast and human cells, Maf1’s association with RNA Polymerase III is regu-
lated through phosphorylation. Under favorable conditions, Maf1 is phosphorylated
and unable to bind to the polymerase complex. Under stress, phosphorylation is
inhibited, and Maf1 binds to Pol III to block formation of  the initiation complex
(Vannini et al., 2010). In certain human and yeast cell lines, Maf1 is localized in the
cytoplasm and translocates to the nucleus and nucleolus upon dephosphorylation
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during stress (Roberts et al., 2006)(Shor et al., 2010). In others, it is constitutively
nuclear, but still requires dephosphorylation to associate with Pol III (Wei et al.,
2009)(Kantidakis et al., 2010). We attempted to localize Plasmodium Maf1 by fluo-
rescent microscopy, but were unable to detect it with our current set of  reagents.
Our efforts to assess Pf Maf1’s phosphorylation state have also been unsuccess-
ful. Of  the many phosphoproteomic studies performed on blood stage Plasmodium fal-
ciparum, only two have reported phosphopeptides mapping to Maf1 protein sequence
(Lasonder et al., 2012)(Lasonder et al., 2015). The reported phosphopeptides were
different in each study (pS86 and pS109) and, in each case, were only supported by a
single spectrum. Both are contained within the asparagine rich region within the pro-
tein sequence, and are not conserved across other Plasmodium species. While not the
most attractive candidates, these phospho-sites may merit further study, as they are
located within the “mobile insertion” region of  the protein, which is one of  the ma-
jor sites of  phosphorylation in yeast and human cells. A phosphoproteomic study of
Toxoplasma gondii found evidence for extensive phosphorylation of  its Maf1 ortholog
(Xia et al., 2008) (Note that the T. gondii ortholog of  the protein described in our study
is TGME49_248110, and not the recently described (Pernas et al., 2014) Mitochondria
Associated Facotor 1 (MAF1). The later protein bears no sequence or functional relation
to the former, and only shares its name due to an unfortunate coincidence in naming).
Of  the thirteen phosphorylation sites reported in T. gondii, most are only supported
by a few spectra and are not conserved in the P.falciparum sequence. However, one
site in the acidic tail, a key regulatory region of  the human and yeast orthologs, has
extensive spectral support and aligns well with the P. falciparum S374. This residue
may be the best candidate for future studies of Pf Maf1 regulation.
In human cells, association of  Maf1 with the Pol III complex appears to be reg-
ulated by the mTOR kinase itself  (Shor et al., 2010)(Kantidakis et al., 2010). In yeast,
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this function is performed by the S6K homolog Sch9 upon TOR activation (Lee et
al., 2009)(Huber et al., 2009), though a single study has suggested the yeast TOR ho-
molog may also phosphorylate Maf1 (Wei et al., 2009). Since the Plasmodium genus
lacks a TOR homolog, the Sch9/S6K homolog, erroneously known as Pf PKB, is a
strong candidate for the Pf Maf1 regulatory kinase. In yeast, other kinases in addi-
tion to Sch9 have also been implicated in Maf1 regulation. PKA has been shown to
phosphorylate Maf1 in vivo, though it appears to regulate localization and not associ-
ation with the Pol III complex (Moir et al., 2006)(Lee et al., 2009). The CK2 kinase
has also been implicated in Maf1 regulation in yeast (Graczyk et al., 2011), though
its importance is not clear (Willis et al., 2011). P. falciparum encodes orthologs of
both these kinases (PKA catalytic subunit: PF3D7_0934800, CK2 catalytic subunit:
PF3D7_1108400), and they should be considered potential regulators of Pf Maf1 as
well. It remains possible that Maf1 is not phosphoregulated in P.falciparum, and in-
stead, its activity is regulated through transcriptional and translational control. This
could explain why Pf Maf1 displays an expression bias toward the late stages of  cell
cycle, and why our attempts to over-express an ectopic copy failed unless expression
was attenuated using a weak promoter and a destabilization domain. We observed
increased pre-tRNA expression in the PB-11 mutant relative to wild type cells in
normal culture medium, suggesting Pf Maf1 performs some level of  basal pre-tRNA
inhibition under normal conditions.
We observed defects in the PB-11 mutant’s ability to recover from not only
prolonged amino acid starvation, but also several other forms of  stress that slowed
growth. We selected fosmidomycin treatment as one such stress for its previously
described ability to trap parasites in schizogeny for several days with little effect on
parasite viability (Howe et al., 2013). The Maf1 mutant displayed decreased recovery
relative to wild type cells upon release from fosmidomycin block. This phenotype
may be due to a secondary effect of  the mutant’s inability to regulate tRNA synthe-
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sis. Fosmidomycin inhibits the non-mevalonate isoprenoid biosynthesis pathway in
the apicoplast. One of  the direct products of  this pathway is dimethylallyl pyrophos-
phate (DMAPP), which serves as a substrate for the isopentenylation modification
of  certain tRNAs in eukaryotes, a process likely to be conserved in Plasmodium spp.
(Guggisberg et al., 2014). In yeast, there is evidence for a Maf1-dependent recip-
rocal relationship between tRNA synthesis and the isoprenoid biosynthesis pathway
(Kaminska et al., 2002), and in fact, overexpression of  yeast Maf1 to suppress tRNA
transcription has been used to increase isoprenoid yield for potential commercial
purposes (Liu et al., 2013). The decreased recovery of  the PB-11 Maf1 mutant may
in part be a result of  depletion of  the residual isoprenoid pool due to the mutant’s
elevated pre-tRNA production.
Babbitt et al.’s description of  the dormancy-like slow-growth response of Plas-
modium falciparum upon isoleucine starvation was the first thorough documentation
of  the parasite’s ability to modulate its growth rate in response to environmental
changes (Babbitt et al., 2012). However, after being unable to implicate any specific
molecular pathways in the response (ie: GCN2/Pf IK2 - IF2α), and after observing a
dose-dependence between isoleucine concentration and growth rate, they concluded
that the parasite does not actively regulate its growth, and that isoleucine is likely the
rate-limiting factor in progression of  the cell cycle. We feel this conclusion may be
premature. Similar conclusions were drawn in other organisms, such as yeast, until
it was demonstrated that chemical or genetic inhibition of  TOR induced the same
transition into stationary phase as nutrient starvation, and that partial inhibition of
TOR slowed the cell cycle in a similar manner as nutrient limitation (Barbet et al.,
1996)(Powers et al., 2006)(Loewith and Hall, 2011). It is well established that dif-
ferent P. falciparum isolates display a wide variation in the length of  the cell cycle and
average number of  merozoites produced in each cycle (Reilly et al., 2007)(Reilly Ay-
ala et al., 2010), indicating that genetic factors contribute to parasite growth. We
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previously demonstrated that the single point mutation that confers artemisinin re-
sistance can change the growth rate of  a parasite line even when isoleucine is limiting
(Chaper 1). The fact that these parasites exhibit increased recovery from both star-
vation and artemisin-induced growth retardation implicates an underlying pathway
that regulates growth. We believe our description of Pf Maf1’s role in maintaining
viability upon growth retardation further supports the existence of  such a pathway.
The remaining components of  the pathway, however, have yet to be identified.
In other eukaryotes, the TORC1 complex itself  is not the sensor for amino acids,
but the hub through which the signal is transduced. The most upstream components
that bind and detect amino acids such as leucine (Wolfson et al., 2016) and arginine
(Chantranupong et al., 2016) in human cells, are not conserved in yeast and other dis-
tal branching lineages. It is possible that Plasmodium has retained its upstream sensors
and the downstream effectors (eg: Pf PKB and Pf Maf1) while losing the intermediate
signaling steps, such as TORC1. Studies in mammalian cells have found evidence that
the class III PI3K HsVps34 increases PI(3)P production in the presence of  amino
acids upstream of  mTOR, leading to increased phosphorylation of  S6K (Nobukuni et
al., 2005)(Byfield et al., 2005). This is reminiscent of  the observation that Pf PI3K in-
hibition by artemisinin inhibits Pf PKB activity in P. falciparum (Mbengue et al., 2015).
However, given that Pf PI3K is associated with both hemoglobin import for digestion
and the reclamation of  amino acids through autophagy, we would like to entertain the
possibility that artemisinin inhibition of  PI3K induces intracellular starvation of  (all)
amino acids, triggering the same growth retardation response as removal of  isoleucine
from the extracellular medium. This would explain why proteasome inhibitors show
synergistic effects with artemisinin (Dogovski et al., 2015), as they block the cell’s last
remaining means of  reclaiming amino acids.
Homologs of  other eukaryote pathways that regulate growth, in addition to
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TORC1, are conserved in the P. falciparum genome. It is possible that Maf1 or the
responses to isoleucine or artemisinin are affected by these pathways. Plasmodium has
a clear homolog of  Protein Kinase A (PKA) (PF3D7_0934800), and also has a kinase
that resembles AMPK/Snf1 (PF3D7_0934800). Neither has been implicated in the
regulation of  parasite growth rate to date. In other organisms, both pathways play
roles in the direct or indirect detection of  glucose levels (Conrad et al., 2014). The
fact that both wild type cells and the PB-11 Maf1 mutant equally retard growth in de-
creased glucose suggests that the mechanism the parasite uses to detect and respond
to glucose is unlikely to be also responsible for Maf1 regulation.
The Unfolded Protein Response (UPR) that detects the accumulation of  un-
folded proteins in the endoplasmic reticulum is another pathway capable of  regulat-
ing cellular growth in mammalian cells. P. falciparum has a greatly reduced UPR path-
way, and notably lacks the highly conserved transcription factors (IRE1, ATF6) that
define the yeast and human response to unfolded proteins (Gosline et al., 2011)(Har-
but et al., 2012). Consequently, Plasmodium has been found to be particularly sensitive
to ER stress-inducing agents such as DTT (Chaubey et al., 2014). A recent, massive
transcriptomics effort found that artemisinin-resistant parasites appear to have higher
steady state levels of  chaperone complexes normally associated with the UPR in other
organisms, and suggested the higher expression of  these factors may be protective
against artemisinin (Mok et al., 2015). However, at present, artemisinin resistant par-
asites have not been shown to be more resistant to ER stress than wild type parasites,
and artemisinin-derivatives have not been shown to induce ER stress. In mammalian
cells, the UPR is capable of  slowing and arresting cell growth by phosphorylation
of  eIF2α by the ER-unfolded protein sensor and kinase PERK (Brewer and Diehl,
2000)(Hamanaka et al., 2005). The P. falciparum genome does encode a kinase (Pf PK4,
PF3D7_0628200) with modest similarity to mammalian PERK (Gosline et al., 2011),
and P.falciparum eIF2α is phosphorylated upon DTT treatment (Chaubey et al., 2014),
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though PK4 has not been implicated in this phosphorylation. The link between an
enhanced-UPR and the ability of  artemisinin-resistant parasites to survive and recover
from artemisinin-induced growth retardation is intriguing. However, at this stage
there is too little evidence to definitively make this connection. ER stress has not
been shown to slow or arrest the cell cycle in P. falciparum (it does not in yeast)(Henry
et al., 2010), and blocking phosphorylation of  eIF2α upon isoleucine starvation has
no impact on growth retardation or survival, suggesting a different pathway regu-
lates slow growth at least under conditions of  isoleucine starvation. Maf1 has not
been demonstrated to be regulated under ER stress or be part of  the UPR in other
organisms.
Unlike TOR, Maf1 has never been shown to arrest or retard growth on its own.
It is instead needed to maintain viability during the period of  stress or nutrient lim-
itation, much as we observed in P. falciparum. It will be interesting to see whether
the PB-11 Maf1 mutant also displays defects in recovery from artemisinin-induced
growth-retardation. The genetic background of  the PB-11 mutant is NF54, which is
acutely sensitive to artemisinin. The current standard for evaluating artemisinin resis-
tance, the Ring Survival Assay (Witkowski et al., 2013), is not optimized for detecting
sensitivity well below that of  resistant clinical isolates. Instead, 0-3-hour ring LD50
assay (Dogovski et al., 2015) will need to be adapted for this mutant. Nonetheless,
it is intriguing that the single point mutation in the K13 gene that confers artemisin
survival also displays increased survival upon prolonged amino acid starvation, and
greater suppression of  tRNA expression. If  growth is actively regulated in Plasmodium
by a residual TORC1 pathway as we hypothesize, then the K13 mutation, and the
subsequent elevation in Pf PI3K levels (Mbengue et al., 2015), may allow the parasite
to more effectively shut down growth when faced with undesirable circumstances,





A full length Plasmodium falciparum Maf1 coding sequence was synthesized with codon
usage optimized for S. cerevisiae expression (Genscript). Using Gibson Assembly
(NEB, #E2611S), the core region of Pf Maf1 (amino acids 237-346) was fused be-
tween the S. cerevisiae N-terminus (amino acids 1-233) and C-terminal “acidic tail”
(amino acids 338-395). The resulting chimeric open reading frame was cloned into
the BamHI and XhoI sites of  the yeast expression vector p416-Met25-3xHA. The full
length yeast Maf1 open reading frame (YDR005C) was similarly cloned into the same
vector. The Maf1∆ knockout line (BY4741 MATa library, ∆YDR005C) was trans-
formed using the LiAc/ssDNA/PEG method (Gietz and Woods, 2002). Survival
assays were carried out on synthetic minimal dextrose medium lacking uracil (for
plasmid selection) and methionine (to de-repress the Met25 promoter for transgene
expression) with or without 10nM rapamycin (Cell Signaling Technologies, #9904).
Parasite Culture and Media
Parasites were cultured using standard methods (Jensen and Trager, 1977) in flasks
gassed with a mixture of  90% N2, 5% CO2, 5% O2 (Airgas, #Z03NI9022000033).
Normal culture medium consisted of  RPMI 1640 with L-glutamine and 25 mM
HEPES (Corning, #10-041-CV), with 5.0g/L Albumax II Lipid-Rich BSA (Ther-
moFisher Scientific, #11021029), 3.7mM Hypoxanthine, and 50µg/mL gentamicin.
The Isoleucine deficient medium consisted of  10.3g/L RPMI 1640 Ile-Dropout
medium (US Biologicals, #R9014), supplemented with 2.0g/L NaHCO3, 6.0g/L
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HEPES, 5.0g/L Alubmax II, 3.7mM Hypoxanthine, and 50µg/mL gentamicin. The
8µM Isoleucine medium was the same as the Isoleucine medium, except was sup-
plemented with 8µM L-Isoleucine. The 20% Glucose media consisted of  8.4g/L of
No Glucose RPMI 1640 (Sigma-Aldrich, #R1383), with 2.0g/L NaHCO3, 6.0g/L
HEPES, 5.0g/L Alubmax II, 3.7mM Hypoxanthine, 50µg/mL gentamicin, and
0.4g/L glucose. Fosmidomycin was obtained from Sigma-Aldrich (#F8682-5MG),
and Geranylgeraniol was obtained from Santa Cruz Biotechnology (sc-200858).
Flow Cytometry
For each sample to be analyzed, 1mL of  parasite culture was pelleted and resuspended
in 1mL of  PBS containing 4%w/v paraformaldehyde. Samples were rocked at 4oC for
20-30h of  fixation. Samples were then pelleted and resuspended in PBS containing
0.1% v/v Triton-X 100 and rocked at room temperature for 1h for permeabilization.
This process was then repeated three additional times with PBS (without Triton-X
100) to remove as much hemoglobin as possible. Samples were then diluted approx-
imately 100-fold into normal culture medium containing 1x SYBR Green I (Ther-
moFisher Scientific, #S7563) and analyzed on a FACSCalibur (BD Biosciences) flow
cytometer. The resulting data was further analyzed using FLOWJO 10.0.7 analysis
software.
Transfection
The DD24-Maf1 construct was synthesized (Genscript) with N-terminal 3xHA tag
followed by a DD24 destabilization domain and a yeast codon optimized Maf1 open
reading frame (the same synthesized construct used for yeast complementation). This
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open reading frame was cloned into the XhoI and XmaI sites of  the vector pLN-
mRPL2pr to generate pLN-mRPL2pr-DD24-Maf1. This vector was used to trans-
fect Dd2attB parasites (Nkrumah et al., 2006) by the pre-loading method (Deitsch
et al., 2001) using a modified Bxb1 integrase transfection method (Spalding et al.,
2010). Stably transfected cells were maintained with 2.5µg/mL Blasticidin S. The
Shield ligand was obtained from Aobious (#1848).
Genome Sequencing and Analysis
High quality, high molecular weight genomic DNA was prepared from 400mL of  2%
hematocrit, ~10% parasitemia PB-11 culture enriched in late stage parasites. Para-
sites were liberated from erythrocytes by saponin treatment and washed twice with
PBS to remove excess hemoglobin. The resulting parasite pellet was used as start-
ing material for genomic DNA isolation using the Blood and Cell Culture Mini Kit
(Qiagen, #13323). Genomic DNA was sent to Axeq Technologies (Seoul, South Ko-
rea) care of  MacrogenUSA (Maryland, USA) for library preparation and sequencing.
An amplification-free library (Kozarewa et al., 2009) was sequenced by paired-end
sequencing to 73x coverage using an Illumina HiSeq2000.
Sequencing Analysis
The analysis of  the sequencing data largely followed the protocol described by Balu et
al. (Balu et al., 2013), which previously sequenced the NF54 clone that was used as the
parental line in the transposon screen which produced the PB-11 mutant (Balu et al.,
2009). Two sets of  paired end reads for the parental NF54 clone, produced by two dif-
ferent sequencing platforms, were obtained from the European Nucleotide Archive
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(ERS038926 and ERS184445). These reads were used to “update” the PlasmoDB-
26 P. falciparum 3D7 genome sequence using ICORN as part of  the PAGIT software
package (Swain et al., 2012). Seven iterations of  ICORN generated 561 1bp sub-
stitions and 774 small insertions or deletions across the entire reference genome.
The PB-11 reads were aligned to this updated reference sequence using bwa (Li and
Durbin, 2009) with the default parameters. Approximately 82% of  reads aligned to
the reference sequence. The resulting sam file was sorted, indexed, and filtered of
duplicates using picard-tools v1.119. Reads were re-aligned around indels using The
Genome Analysis Toolkit (GATK) (McKenna et al., 2010), and raw variants were
called using the GATK HaploTypeCaller with ploidy set to 1. The raw variants were
then filtered using vcftools v0.1.13 (Danecek et al., 2011) to only include calls with
a quality score greater than 60 and a minimum depth of  10 reads. The program
snpEff  v3 (Cingolani et al., 2012) was then used to filter only those variants found
within open reading frames. This resulted in 32 potential variants within open read-
ing frames. However, upon visual inspection using the Integrated Genomics Viewer
v2.3.9 (Robinson et al., 2011), every call was found in either a low complexity (e.g:
an extended mononucleotide tract) or repetitive region. In each case, there was read
support for the reference sequence, leaving us to conclude that these variants are
more than likely false-positives. To verify that our pipeline was indeed capable of  de-
tecting variants, we re-ran the pipeline using the reads from the C9 piggyBac insertion
mutant sequenced by Balu et al. (ENA ERS038913)(Balu et al., 2013). We were able
to easily detect the same two SNPs reported previously.
mRNA Expression qPCR Timecourse
Synchronous cultures were established by sequential sorbitol treatments. For
each time point, 50mL of  2% hematocrit culture at approximately 10% par-
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asitemia was pelleted and immediatey disrupted with 10mL of  TRIzol (Ther-
moFisher Scientific, #15596018), and used for subsequent phenol/chloroform
extraction and ethanol precipitation, as per the manufacturer’s protocol. First
strand cDNA synthesis was performed using a mixture of  oligo-dT and ran-
dom hexamers using Superscript III (ThermoFisher Scientific, #18080044)
using the standard protocol. For quantitative PCR, the Maf1 transcript was
amplified using the forward primer 5’-GATGCCCACGATCGTTTTAT-3’
and reverse primer 5’-CGGAGCTAAATATTTGTGTATTGC-3’. The seryl-
tRNA ligase transcript, PF3D7_0717700, was used as an internal control,
with 5’-AAGTAGCAGGTCATCGTGGTT-3’ as a forward primer and 5’-
TTCGGCACATTCTTCCATAA-3’ as reverse primer. Quantitave PCR was per-
formed using SYBR Green PCR Master Mix (ThermoFisher Scientific, #4309155)
on a StepOnePlus (ThermoFisher Scientific) Real-time PCR system.
5’-RACE
RNA was extracted from 50mL of  2% hematocrit, 10% parasitemia mixed stage cul-
ture using TRIzol (ThermoFisher Scientific, #15596018). 5’-RACE was performed
using the FirstChoice RLM-RACE Kit (ThermoFisher Scientific, #AM1700). The
resulting PCR product was cloned using the CloneJET PCR Cloning Kit (Ther-




Recombinant protein expression and Antibody production
For recombinant protein production, the Plasmodium berghei Maf1 ortholog
(PBANKA_0718500) was selected instead of  the P. falciparum ortholog, as it is
much smaller and contains a short repeat in the place of  the P. falciparum asparagine-
rich region. Outside this region, the sequences are nearly identical. The P. berghei
Maf1 sequence was synthesized with E. coli optimized codon usage (DNA2.0) with
an N-terminal 6xHis tag in a T7 promoter expression plasmid. Protein expression
was conducted in NiCo21(DE3) cells (NEB, #C2529). Expression was performed
in 1L cultures induced at an OD600 of  3.0 with 0.5mM IPTG in Terrific Broth for
20h at room temperature. Cells were lysed by sonication, and protein was isolated
using Ni-NTA agarose (Qiagen, #30210). The recombinant protein was used to
produce antiserum from two separate Guinea Pigs by Cocalico Biologicals (Penn-
sylvania, USA) using the standard protocol. Antiserum was affinity isolated against
the recombinant PbMaf1 protein. Western blots were visualized using a LI-COR
Odyssey imaging system with 680RD linked anti-mouse (LI-COR, #925-68070) and
anti-guinea pig (LI-COR, #925-68077) secondary antibodies. The 1-10b Pf GAPDH
monoclonal (mouse) (Daubenberger et al., 2003) was used as a loading control.
Growth Curves
Asynchronous parasite cultures were maintained under the conditions described and
sampled every 48h to quantify parasitemia by flow cytometry. Cultures were then di-
luted between 2 and 10-fold to maintain a parasitemia between 0.5-1.0% parasitemia
and the dilution factor was recorded. The growth at each time point was measured
as the parasitemia multiplied by the dilution factor of  the previous dilution. The final
dataset was normalized such that the initial parasitemia for each line started at 1.0 to
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account for differences in the starting parasitemias of  the different parasite lines. A
two-factor regression of ln(adjusted parasitemia) ∼ hour + genotype was fit for each
condition to test the effect of  parasite genotype on growth rate with time as a covari-
ate. Doubling time (tD) was calculated for each line from single factor regressions
against time alone, using tD = log(2)/βo, where βo is the coefficient from the single
factor regression.
tRNATyr intron verification and stem-loop PCR
For tRNA analysis, RNA was isolated using miRvana miRNA Isolation Kit
(ThermoFisher Scientific, #AM1560) to specifically enrich small RNAs. Due to the
inherent high-stability of  tRNA secondary structure, a modified reverse-transcription
protocol was employed. Total small RNA was mixed with 5µM of  the RT-primer
5’-ttacttgtacagctcgtccatgccgagaTCCGATGAACCGGAATCG-3’ which anneals to
the 3’ end of  the tRNATyr (PF3D7_0702800) sequence but contains a RACE-like
5’ extension of  an unrelated primer sequence for subsequent PCR amplification
(to avoid amplifying the genomic locus). The small RNA-primer mixture was
heated to 98oC for 5min, then cooled slowly to 4oC. Reverse transcription was
then performed using Superscript III (ThermoFisher Scientific, #18080044) by the
manufacturers protocol, with the exception that it was performed at the elevated
temperature of  65oC for 1h to minimize the effects of  tRNA secondary structure.
The cDNA was then amplified using Phusion High-Fidelity Polymerase (NEB,
#M0530L), using the forward primer 5’-CCGATGATAGCTCAGTTGGTAGA-3’,
which anneals to the 5’ end of  the tRNATyr sequence, and the reverse primer
5’-CTTGTACAGCTCGTCCATGCC-3’, which anneals to the RT-primer’s 5’ ex-
tension. The resulting PCR product was cloned using the CloneJET PCR Cloning
Kit (ThermoFisher Scientific, #K1231) and sequenced (MacrogenUSA) to verify
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the excision of  the predicted 11nt intron.
pre-tRNATyr stem-loop qPCR
For analysis of  of  pre-tRNATyr, highly synchronous parasites cultures were initiated
by percoll-sorbitol treatment to generate 50mL of  2% hematocrit culture between 5%
and 10% parasitemia with a maximum parasite age of  4hpi. These cultures were then
washed three times in 50mL PBS and resuspended in either normal media or media
lacking isoleucine, then incubated for 24h prior to harvesting. Cultures were pelleted
and treated with 0.1% Saponin in PBS, and washed twice with 50mL PBS to remove
liberated hemoglobin. A small RNA sample was then isolated from parasite pellets
using the miRvana miRNA Isolation Kit (ThermoFisher Scientific, #AM1560)
according to the manufacturer’s protocol. In order to specifically detect the presence
of  the 11nt intron in the pre-tRNATyr, a stem-loop PCR method originally developed
for miRNA detection (Chen et al., 2005)(Varkonyi-Gasic et al., 2007) was adapted.
In this method, a self-annealing 5’ stem-loop extension to the RT-primer both adds
length to the final product for downstream qPCR amplification, and may also provide
additional stability for the annealing of  the short complementary primer sequence due
to stacking interactions provided by the stem-loop. For reverse transcription, small
RNA samples were combined with a 5µM mixture of  the stem-loop RT-primers 5’-
GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACataaccatttc-
3’ and GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATAC-
GACcagcattctga, which anneal to the pre-tRNATyr intron and the 3’ end of  the 5.8s
rRNA respectively. The primer-RNA mixture was heated to 98o for 5min then
cooled to 4oC. Reverse transcription was carried out at 65oC for 1h to overcome
RNA-secondary structure, but otherwise followed the manufacturers protocol
for Superscript III (ThermoFisher Scientific, #18080044). Quantitative PCR was
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performed using the common reverse primer 5’-CAGTGCAGGGTCCGAGGT-
3’ which anneals to the shared stem-loop structure, and the gene-specific
forward primers 5’-AGTTGGTAGAGCGGCAGACT-3’ (tRNATyr) and 5’-
AGCAAAACGCGATAAGCAAT-3’ (5.8s rRNA) on a StepOnePlus Real-Time
PCR system (ThermoFisher Scientific) using the Power SYBR Green Master Mix
(ThermoFisher Scientific, #4367659).
Puromycilation Assay
Cultures were initiated using percoll-sorbitol synchronization to produce 50mL cul-
tures at 2% hematocrit at approximately 10% parasitemia. Cultures were then pel-
leted and washed three times with 50mL PBS and resuspended in either normal or
isoleucine-lacking medium. After 24h, puromycin was added to a final concentration
of  1.0µM and parasites were incubated for an additional 1h. Samples were then pel-
leted and resuspended in 50mL 0.1% Saponin in PBS, and subsequently washed twice
with 50mL PBS to remove hemoglobin. Parasite pellets were then lysed using RIPA
buffer containing protease inhibitors. For ELISA, 500ng/well of  each biological
replicate was separately probed with either the anti-puromycin monoclonal antibody
3RH11 (Kerafast, #EQ0001), or monoclonal anti-Plasmodium falciparum GAPDH as
an internal control. As a negative control, parasites grown in normal media were
treated with 10µg/mL cyclohexamide simulataneously with puromycin to arrest pro-




All statiscal analyses were performed using R version 3.2.3 (2015-12-10)(R Core
Team, 2015). T-tests, linear and logistic regressions, and some figures were generated
using R base functions. The drc package (Ritz, C. and Streibig, J.C., 2005) was used
for determining the 50% survival point of  PB-11, and the ggplot2 package (Wickham,




Re-evaluation of mutants defective in the
early stages of gametocyte differentiation
and identification of the Start-like




Unlike a dormancy-like response, the transition of  asexual reproducing blood-stage
malaria parasites to transmissible sexual forms known as gametocytes represents a
true cell cycle exit and differentiation event. Our lab previously conducted a forward
genetic screen to identify genes necessary for gametocytogenesis. Analysis of  the
mutants obtained from the screen showed a temporal hierarchical order, suggesting
several mutants may be affected at the earliest stages of  commitment to differentia-
tion. Here, we re-evaluate these findings in light of  the discovery of  an underlying
mutation present in the starting population of  cells used for the screen, and find that
the basis of  the mutant phenotypes observed may be more complex than originally
appreciated. Furthermore, using a newly available transgenic parasite line in which
gametocytogenesis can be induced, we mapped the timing of  the Start-like check-





Previous chapters have investigated whether Plasmodium falciparum is capable of  en-
tering a programmed state of  dormancy when faced with unfavorable environmental
conditions. While there is evidence that artemisinin derivatives and amino acid starva-
tion can affect the parasite’s growth rate, and that different genes (e.g: Maf1, K13) can
affect a parasite’s ability to recover from growth-retarding forms of  stress, we found
no evidence of  a specialized differentiation pathway into a dormant state. However,
there is a well-established differentiation program that Plasmodium falciparum uses to
exit the cell cycle: the transition of  the parasite from the asexual cycle to the sexual
differentiation pathway, or as it is commonly referred, gametocytogenesis.
Gametocytes are the only form of  the malaria parasite transmissible to the
mosquito vector. Once ingested by mosquito, gametocytes rapidly differentiate in the
midgut into male and female gametes, fuse to form a zygote, and progress through
the mosquito stages of  the parasite lifecycle. P. falciparum mature gametocytes are
morphologically distinct from the asexual forms (Figure 4.1), and the process by
which they develop from a ring stage into elongated, transmissible forms over seven
to ten days has been well documented. However, the mechanism that triggers exit
from the asexual cycle and commitment to the sexual lineage remains poorly under-
stood.
The first important discovery in regards to commitment to gametocytogenesis
was the finding that all merozoites from single schizont are committed to the same
developmental pathway (Figure 4.1) (Bruce et al., 1990). All merozoites either de-
velop into gametocytes, or continue on with the asexual cycle. Later work revealed
that this finding holds true for the sex of  gametocytes as well: a single schizont ei-




2000). Thus, commitment to either the sexual or asexual lineage is already established
prior to the end of  schizogeny, sometime in the preceeding ~45-hour asexual cycle.
In an effort to understand this commitment process at the molecular level, our
lab conducted a forward genetic screen to identify genes involved in the commitment
process (Ikadai et al., 2013). Most of  this work was completed prior to my joining
the lab. Initial results were quite promising, though, as describe below, follow-up
work (performed by me) has revealed that the interpretation of  some of  our findings
may be more complex than originally believed. What follows is a description of  my
contributions to this study and an effort to interpret our findings in the context of
our current understanding of  gametocytogenesis. Lastly, using a reagent generated by
others and methods similar to those used in Chapter 2, we have attempted to determine
the timing of  commitment point to gametocytogenesis in the asexual cycle.
Results
Expression analysis of transposon insertion mutants suggests an epistatic or-
dering of gametocyte mutants
Hiromi Ikadai and Kathryn Shaw Saliba conducted a forward genetic screen for ga-
metocyte development using insertional-mutagenesis with the piggyBac transposon
(Ikadai et al., 2013). After a series of  transfections, they isolated 189 parasite clones
containing transposition events. Of  these, 29 clones, representing 16 distinct inser-
tion events, did not produce detectable gametocytes when analyzed. Inverse PCR
was used to identify the sites of  insertion. Of  the 16 distinct insertions, 5 were within
annotated open reading frames and the remaining 11 occurred in intergenic regions.
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While many of  the genes associated with the insertions had annotated functions or
identifiable domains, as a whole, the collection of  genes did not suggest an obvious
shared pathway or mechanism.
The insertion mutants were determined to be gametocyte non-producers based
on the absence of  observable gametocytes in Giemsa smears. However, Giemsa
staining can only be used to distinguish gametocytes from asexual cells starting from
the Stage II morphological form of  gametocytogenesis through to maturity (Stage
V), as these stages are clearly morphologically distinct from the asexual cycle. Stage
II gametocytes manifest approximately 48 h into gametocyte development, meaning
that the mutants could produce ring stage gametocytes or Stage I gametocytes (which
are indistinguishable from asexual trophozoites on Giemsa smears) prior to reaching
the point at which the gametocytogenesis program is affected. No known markers
exist to identify ring stage gametocytes. However, the expression of  several early
gametocyte proteins, including Pf mdv1 (Furuya et al., 2005), has been assigned to
Stage I gametocytes.
K. Shaw Saliba screened the sixteen gametocyte mutant clones for their ability
to produce Pf mdv1-expressing Stage I gametocytes using an immunofluorescence
assay. Seven of  the sixteen mutants were found to produce rare, Pf mdv1-positive
cells. No Stage I cells were detected in the remaining mutant clones. From this find-
ing, we reasoned that the mutations in some of  the mutants must affect the transition
from Stage I of  gametocytogenesis to later stages of  maturity. The mutations in the
remaining clones must affect either the ring-stage gametocyte, or events in the pre-
ceding cell cycle necessary for establishment of  committment. Since the timing of
the commitment event is unknown, these mutant parasites could potentially arrest
development anywhere in a 72h window: from the earliest point of  the ring stage of
the preceding generation, through the 45-hour cell cycle, or anytime during the 24 h
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ring-stage gametocyte prior to development into Stage I.
If  we assume that once commitment to the gametocyte lineage is established
a distinct transcriptional program is activated to drive differentiation program, then
it may be possible to identify differential arrest points of  each mutant clone based
on differential transcript expression profiles. We attempted this by performing RT-
PCR for the expression of  a panel of  30 genes on each of  the sixteen mutants as
well as the ‘parental’ gametocyte-producing clone. The genes analyzed included all
the genes identified as affected by transposon-insertion in our screen, as well as a
collection of  transcripts previously reported in other studies to be expressed across
gametocytogenesis. K. Shaw Saliba performed RT-PCR for each transcript on mixed-
stage RNA from each mutant clone, and each clone was scored in a binary fashion,
as either expressing the transcript or not.
Several transcripts displayed differential expression across the mutant collec-
tion, with some mutants expressing most of  the analyzed transcripts, and others only
expressing a select few. I performed hierarchical clustering on the expression data to
see whether any patterns could be discerned. The results of  my analysis are shown
in Figure 4.2. The transcript analysis clearly separates the mutants into two major
clusters and several sub-clusters. Importantly, one of  the clusters consists of  all the
clones previously found by independent means to produce Stage I gametocytes (plus
one additional clone), validating the hierarchical ordering.
We do not know how to interpret the sub-clusters of  the non-Stage I produc-
ing mutants. Presumably, those that produce more transcripts proceed further into
gametocytogenesis program than those that produce fewer transcripts, such as the
ring-stage just prior to Stage I development. Those producing the fewest transcripts




deficient in the ability to commit to gametocytogenesis altogether. Resolving these
points of  arrest will require additional early markers and a better understanding of
the earliest stages of  commitment and development.
All insertion mutants carry a non-synonymous mutation in AP2-G that likely
affects gametocyte development
In 2014, a year after our transposon-insertion screen was published, two comple-
mentary studies were published identifying an AP2 domain-containing transcription
factor as the key regulator of  gametocyte development in both P. falciparum (Kafsack
et al., 2014) and the model murine parasite P. berghei (Sinha et al., 2014). The authors
concluded that this transcription factor, named AP2-G (PF3D7_1222600), was likely
the earlierst-acting regulator of  gametocyte development. Furthermore, the authors
reported that several gametocyte-deficient lab strains, that had been used for decades
to study gametocytogenesis, all contained inactivating mutations in AP2-G. The au-
thors concluded that spontaneous mutations in AP2-G were likely the cause of  the
loss of  gametocytogenesis frequently observed after prolonged maintenance of  par-
asites in culture, as disruption of  AP2-G and elimination of  gametocytogenesis con-
ferred a growth advantage over gametocytogenesis-competent wild type parasites.
AP2-G was not one of  the genes identified in our forward genetic screen, despite
the fact that we obtained insertions in several loci multiple times, suggesting some
degree of  saturation mutagenesis was attained. To investigate further, we sequenced
the coding sequence of  AP2-G in our insertion mutants. To our surprise, every single
one of  the 29 insertion mutants contained the same guanine to thymine transversion
at position 6487 of  the AP2-G open reading frame. This transversion is in the first




A valine to leucine conversion is considered to be a conservative mutation, as
these two amino acids are both hydrophobic and have a similar size and structure.
However, given that the mutation was within the AP2 DNA binding domain,
the finding was somewhat concerning. We re-examined the gametocytogenesis-
competent 3D7 clone used as the ‘parental’ line for transposon screen to see if  it too
carried this mutation.
Using mixed-stage genomic DNA from the 3D7 parental line, a region sur-
rounding the G6487T mutation was amplified and cloned into a shuttle vector. Plas-
mids were isolated from 42 independent E. coli colonies and sequenced. Of  the 42
colonies, five carried the G6487T transversion while the other 37 displayed the wild
type G allele. This suggests that the parental line may be a mixture of  both AP2-G
allelic variants, with the mutant T allele occurring at frequency of  roughly 0.12 (5/42).
To investigate further, the parental 3D7 line was cloned by limiting dilution. A
total of  46 clones were obtained and screened for the presence of  the G6487T mu-
tation. Of  these, 10 clones carried the mutant T allele, corresponding to a frequency
of  0.21, which is not statistically different than the 0.12 frequency obtained from
PCR owing to the small sample sizes (p = 0.08, Poisson test) (Figure 4.3B). Impor-
tantly, of  the 189 transposon insertion mutants obtained after transfection, 29 did not
produce gametocytes, for a frequency of  0.15. The gametocyte-competent insertion-
mutants were discarded after screening, so cannot be tested for the presence of  the
G6487T mutation. However, the fact that all of  the gametocyte-deficient mutants
obtained in the screen carried the mutation and were obtained at a frequency similar
to the frequency of  the mutant allele in the parental culture, raises the concern that




culture and may not have been due to mutation from insertional mutagenesis.
The 46 clones from the parental culture were screened for their ability to pro-
duce mature gametocytes. Of  the 36 clones carrying a wild type G at position 6487,
8 did not produce mature gametocytes (Figure 4.3C). The remainder of  the AP2-G
coding sequence was not sequenced in these clones to look for additional mutations.
All of  the 10 clones carrying the G6487T mutation failed to produce gametocytes
after multiple assays. This frequency is statistically above what would be predicted
if  the gametocytogenesis-deficiency were due to the same “background” level defi-
ciency observed in the 36 clones carrying the wild type allele (p = 0.0001, Poisson
test).
It is difficult to reconcile these findings with the hierarchical clustering of  the
mutants described earlier. The insertion mutants appear to arrest at different stages
of  differentiation, yet all carry the same mutation that appears to block gametocyto-
genesis. The 46 sub-clones from the parental line were only screened for their ability
to produce mature gametocytes, and were not tested for the ability to produce Stage
I gametocytes. Perhaps the mutation(s) cause(s) an arrest at Stage I of  gametocyte
development, but has/have little to no effect on earlier events. If  this is the case, the
validity of  the seven mutants found to produce Stage I gametocytes will need to be
re-examined. Regardless, the finding of  the G6487T complicates the interpretation
of  the insertional-mutagenesis screen. Any future work on these mutants will have
to take this mutation into consideration.
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The PB-11 Maf1 mutant displays no defects in gametocytogenesis
One of  the insertion mutants obtained in the screen (2A11) had a piggyBac insertion
in the intergenic region between two genes on Chromosome 4 (Figure 4.4A). Ini-
tial RT-PCR screening of  the mutant found that the gene proximal to the insertion
site (PF3D7_0416600) was not affected at the transcript level by the insertion, but
expression of  the transcript of  the distal gene (PF3D7_0416500) was completely in-
hibited, leading us to attribute the gametocytogenesis-deficiency phenotype to the
distal gene. Subsequent RT-PCR analysis found that the transcript was not inhibited
afterall (Figure 4.2), complicating this interpretation.
The distal gene to which the phenotype was initially attributed encodes the Plas-
modium falciparum homolog of  the RNA Pol III repressor Maf1. The identification of
the mutant in this screen is what led to our interest in this gene, ultimately resulting
in the studies performed in Chapter 3.
As detailed in Chapter 3, we obtained an independent transposon insertion mu-
tant (identified as PB-11) produced by the lab of  John Adams (Balu et al., 2009) that
contained an insertion much closer to the Maf1 open reading frame (Figure 4.4A).
Despite insertion of  the transposon into the Maf1 5’ UTR (Chapter 3), the PB-11 mu-
tant still expressed detectable levels of  the Maf1 mRNA and protein, albeit with a
different expression profile from that observed in wild type parasites.
We investigated whether the PB-11 mutant is capable of  producing gametocytes,
and indeed, it produced gametocytes at a high rate. Since the PB-11 mutant is not
a complete knockout, it remains a possibility that the low levels of  Maf1 expression
in this line are sufficient to support gametocytogenesis. However, based on these
results, the assignment of  Maf1 as the causative mutation in the 2A11 clone obtained




HP1-dependent committment to gametocytogenesis occurs in the late ring-
stage
The current model for commitment to gametocytogenesis is centered on activation
the AP2-G transcription factor (Kafsack et al., 2014) (Sinha et al., 2014). Cells that ac-
tivate AP2-G transcription in their current generation will undergo gametocyte com-
mitment in the subsequent generation. How this activation occurs is not understood.
It may be triggered by a signal or may be stochastic. What is clear, however, is that
in its inactive state the AP2-G gene locus is enriched with histone H3K9 trimethy-
lation (Lopez-Rubio et al., 2009) and is bound by the Heterochromatin Protein 1
(HP1)(Flueck et al., 2009), two hallmarks of  transcriptionally-inactive chromatin.
Two recent studies have followed-up on the role of  chromatin modification in
the silencing of  AP2-G expression in the control of  gametocytogenesis commitment.
One study found that destabilization of  the Class II histone deacetylase Pf HdaII in
synchronous parasites in culture causes a dramatic increase in gametocyte develop-
ment in the subsequent generation (Coleman et al., 2014). Class II histone deacetylase
enzymes remove transcription-activating histone acetylation marks to allow for the
deposition of  the transcription-silencing HP1 protein and histone H3K9 trimethy-
lation. Similarly, a second study found that controlled destabilization of  the gene-
silencing HP1 protein itself  also causes an increase in the number of  developing ga-
metocytes in the following generation (Brancucci et al., 2014). In the case of  HP1
destabilization, however, upwards of  50% of  parasites committed to gametocyte de-
velopment. HP1 destabilization is the single most effective inducer of  gametocyto-
genesis reported to date.
HP1 destabilization causes an increase in AP2-G transcript expression in the
first asexual generation, and this high level of  expression is maintained in the subse-
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quent gametocyte development generation (Brancucci et al., 2014). While indirect,
it effectively allows for the controlled induction of  commitment to gametocytoge-
nesis. As discussed above, it is known that commitment occurs in the generation
prior to gametocyte development, but it is not known when in the previous cycle this
commitment occurs.
In the haploid stages of  the yeast S. cerevisiae, treatment with pheromones causes
cells to undergo differentiation into the mating-competent forms. However, treat-
ment with the pheromone must occur prior to a certain point in the cell cycle, known
as Start, for differentiation to occur (Hartwell et al., 1974). Once Start is passed,
cells become refractory to pheromone treatment and complete cell division and form
daughter cells before becoming sensitive to the mating pheromone once again. We
reasoned that there may be an analogous point in the P. falciparum cell cycle before
which AP2-G expression must be activated for gametocytogenesis commitment to
occur.
To investigate this, we obtained the HP1 conditional mutant parasite line pro-
duced by Brancucci et al.. In this parasite line, the HP1 protein has been modified
with a ligand-regulatable degron. In the absence of  the stabilizing ligand, known as
Shield, the HP1 protein is rapidly degraded. Cells maintained in continuous culture in
the presence of  the Shield ligand are indistinguishable from wild type cells. To deter-
mine whether there is a time-dependent effect of  HP1-destabilization (and thereby
AP2-G activation) on commitment to gametocytogenesis, a culture was initiated with
highly synchronous young rings (~3 h post invasion) in the presence of Shield. Every
three hours over the course of  the 45 h cell cycle, an aliquot of  culture was removed,
washed repeatedly, and re-cultured in media lacking Shield to cause HP1 destabiliza-
tion. After 50 h, when all parasites would be expected to have completed the cell
cycle and reinvaded new erythrocytes, heparin was added to each subculture. Hep-
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arin blocks erythrocyte invasion by merozoites (Boyle et al., 2010), and should select
for cells induced to commit to gametocytogenesis during the time course (gameto-
cytes do not produce merozoites), and eliminate asexual cells from the culture. After
another four days of  incubation, after which any induced gametocytes would have
developed well beyond Stage I of  gametocytogenesis, cells were fixed and stained
with an anti-Pf Peg4 antibody and analyzed by flow cytometry. Peg4 is expressed in
gametocytes from Stage I through V and is not expressed in asexual cells (Silvestrini
et al., 2005).
The results of  the analysis are shown in Figure 4.5B. A logistic regression model
fit to the data shows the likelihood commitment to gametocytogenesis decreases as
the hour post invasion of Shield removal increases (p < 2.00x10-16). These results
suggest, just as the Start checkpoint in yeast, that there is a point in the asexual cycle
after which cells become insensitive to AP2-G induction. Based on the model, this
point occurs at approximately 18 hpi, the point at which 50% of  parasites commit
to gametocytogenesis and 50% do not. As in yeast, this point occurs well before
the onset of  DNA replication in the parasite’s cell cycle (~30 hpi, see Chapter 2). In
fact, this point coincides roughly with the transition from the ring stage of  parasite
development to the trophozoite stage.
This finding has potentially important ramifications for our understanding of
the commitment process. If  AP2-G induction and commitment must occur prior to
18 hpi, then it follows that there must be both trophozoite and schizont stages of
the parasite that are irreversibly committed to the gametocyte lineage (Figure 4.6).
Similarly, these data suggest the event that triggers commitment (if  one exists) must
occur during the ring stage, as later stages of  the parasite would be expected to be
refractory to such a trigger. It would be interesting to re-evaluate the pre-Stage I






Many lab strains P. falciparum do not produce gametocytes at all, and those that do
often produce them at very low levels. Our screen for genetic factors affecting ga-
metocytogenesis was an attempt to decipher this complicated process. The mutants
obtained from this screen appeared to arrest development, at least at the transcript
level, at a range of  different stages. Mutants of  this nature could be an invaluable tool
for further understanding what occurs in the cryptic early stages of  gametocytogen-
esis.
However, it appears that all of  our mutants carry a mutation that may have a
direct effect on gametocytogenesis. We have yet to formally demonstrate that this
mutation directly inhibits gametocytogenesis (by, for example, reverting it back to the
wild type allele and restoring gametocytes), but the finding that all parasites carrying
the mutation are incapable in producing gametocytes suggests this may be the case.
Understanding the effects of  this mutation will be key to interpreting the value of  the
mutants from our genetic screen.
Using techniques similar to those employed in Chapter 2, we have determined
that P. falciparum displays a Start-like checkpoint at which commitment to gametocy-
togenesis occurs. This reshapes our understanding of  the black box that is commit-
ment to gametocytogenesis. Using this Start-like checkpoint as point of  reference
will be helpful for studies of  the committed trophozoite and schizont stages as well




Parasite Culture and Media
Parasites were cultured using standard methods (Jensen and Trager, 1977) in flasks
gassed with a mixture of  90% N2, 5% CO2, 5% O2 (Airgas, #Z03NI9022000033).
Normal culture medium consisted of  RPMI 1640 with L-glutamine and 25 mM
HEPES (Corning, #10-041-CV), with 5.0g/L Albumax II Lipid-Rich BSA (Ther-
moFisher Scientific, #11021029), 3.7mM Hypoxanthine, and 50µg/mL gentamicin.
The Shield ligand was obtained from Aobious (#1848).
Clustering
The binary RT-PCR expression data from K. Shaw Saliba (Ikadai et al., 2013) was
used to construct a dissimilarity matrix by Euclidean distance and subsequently hier-
archically clustered by Ward’s method.
PCR cloning and sequencing of the G6487T transversion
Genomic DNA from the parental 3D7-Pfs28::GFP parasite line was amplified
using Phusion High-Fidelity Polymerase (NEB, #M0530L), using the forward
primer 5’-GGAGATATGAATTACAAAAGGCAAT-3’ and reverse primer 5’-
TAGCCATTCTCAATGCACCA-3’ which amplify a 302bp region from 6338 to
6610 of  the AP2-G (PF3D7_1222600) open reading frame. The resulting PCR
product was cloned using the CloneJET PCR Cloning Kit (ThermoFisher Scientific,
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#K1231). Plasmids were isolated from individual E. coli colonies and sequenced
(MacrogenUSA) using the forward primer.
Limiting dilution cloning
The number of  parasites per mL of  culture was determined for the parental 3D7-
Pfs28::GFP parasite line by blood smear and hemocytometer. The culture was then
serially diluted in 10-fold increments down to 10 parasites/mL. A total of  60µL of
this dilution was deposited into 80 wells of  five 96-well plates, such that each well is
expected to receive 0.60 parasites. The wells were then supplemented with 140µL of
a mixture of  standard culture medium and erythrocytes such that each well contained
a final volume of  200µL of  1% hematocrit culture. Every three days, 100µL of  media
was removed and replaced with fresh media containing 0.5% v/v fresh erythrocytes.
After twenty days, 100µL from each plate was used for a SYBR GREEN I plate
reader assay (Smilkstein et al., 2004) to determine positive wells. All wells that scored
positive were subsequently verified by Giemsa smears. A total of  46 parasite clones
were obtained. The AP2-G locus was sequenced as described above.
Gametocyte production for PB-11
An asynchronous culture of  PB-11 parasites was initiated in standard culture medium
at 4% hematocrit at a starting parasitemia of  0.5%. The culture was maintained with
daily media changes but no dilution or subculturing for 14 days. Early stage gameo-




All statiscal analyses were performed using R version 3.2.3 (2015-12-10)(R Core
Team, 2015). T-tests, linear and logistic regressions, and some figures were generated
using R base functions. The drc package (Ritz, C. and Streibig, J.C., 2005) was used
for determining the 50% survival point of  PB-11, and the ggplot2 package (Wickham,







Dormancy, or Robust Growth & Resilience?
Initial observations led several authors to put forth a model of  dormancy to ex-
plain Plasmodium falciparum’s ability to survive artemisinin treatment (Teuscher et al.,
2010)(Witkowski et al., 2010)(Codd et al., 2011)(Cheng et al., 2012). Instead of  a
point mutation decreasing the affinity of  the drug to its target enzyme, or an overac-
tive efflux pump decreasing the intracellular drug concentration, the model proposed
that resistant parasites arrest the cell cycle and enter a state of  low metabolic activ-
ity, surviving silently in the blood stream until conditions become more favorable.
If  true, the ability of  the parasite to enter dormancy could have serious implications
for the future of  malaria control. In theory, a dormancy response could provide
cross-resistance to any number of  other drugs, both those in current use and those
in development, and dormant infections would severely complicate epidemiological
tracking of  infected individuals. Like is the case for dormant P. vivax hypnozoites,
patients believed to be cleared of  parasites could suffer relapsing infections months
to years later. If  dormant parasites were insusceptible to drug treatment, P. falciparum
elimination from endemic areas would be nearly impossible.
However, more recent studies have steered our understanding of  artemisinin
resistance away from dormancy and relapse. If  anything, the results suggest quite
the opposite. Artemisinin appears to have an intracellular target, the Pf PI3K lipid-
kinase, and resistance is conferred through elevation in the target protein’s expres-
sion (Mbengue et al., 2015). Resistance does not appear to be conferred through the
entrance into a dormant state, but an increased ability to recover from the growth-
inhibiting effects of  the drug itself  (Klonis et al., 2011)(Dogovski et al., 2015). Re-




We attempted to study the parasite’s reported ability to enter dormancy when
starved of  the amino acid isoleucine. While many of  our findings supported the ob-
servations of  the previous study (Babbitt et al., 2012), we found no evidence of  dor-
mancy. Starved parasites respond to isoleucine starvation by entering a state of  slow
growth. Yet, surprisingly, there appears to be more parallels between our findings and
the current understanding of  artemisinin resistance than the original dormancy model
suggested. Inhibition of  of Pf PI3K, the purported artemisinin target, induces slow
growth much like that observed with isoleucine starvation, and artemisinin-resistant
parasites grow more robustly under normal conditions and survive prolonged amino
acid starvation much better than their drug-sensitive counterparts. Our study sug-
gests that more robust growth and resilience to growth inhibition seem to be key to
the parasite’s ability to survive both artemisinin treatment and isoleucine starvation.
Over the past decade, there has been an increased focus on the role of  en-
hanced growth signaling in the progression of  human cancers. Many tumors acquire
mutations that elevate signaling through the TORC1 pathway (Guertin and Saba-
tini, 2005)(Cargnello et al., 2015). Over-activity of  this pathway is believed to cause
tumors to grow more robustly, acquire more nutrients, and suppress apoptosis. In-
hibitors of  TORC1 signaling have shown promising results in anti-tumor therapy. We
found that one of  the few residual components of  TORC1 signaling in P. falciparum,
Pf Maf1, is critical for the parasite’s ability to recover from prolonged starvation. The
two genes implicated in artemisinin resistance, Pf PI3K and Pf PKB, are also residual
components of  the TORC1 pathway (Mbengue et al., 2015). Perhaps, as in cancer
chemotherapy, the development of  therapeutics that inhibit these conserved growth
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